RNA-guided DNA Binding Agent and its Delivery System
By redesigning VLPs to accommodate RNA-guided DNA binding agents with modified domains and expanded PAM recognition, the limitations of current VLP platforms are overcome, enabling efficient delivery and precise genome editing with minimal off-target effects.
Patent Information
- Application Number
- PCT/CN2026/097531
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
Current virus-like particle (VLP) platforms face limitations in delivering Cas proteins due to poor compatibility with many Cas orthologs or engineered variants, structural and size constraints, and restricted PAM flexibility, hindering precise and adaptable genome editing applications.
Redesigning VLP architectures and optimizing cargo-loading mechanisms to enable efficient delivery of a wider spectrum of Cas nucleases, including RNA-guided DNA binding agents with modified HNH and RuvC domains, and broadening PAM recognition to sequences like NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA.
Achieves efficient delivery of diverse Cas proteins with minimal off-target activity and high gene editing efficiency, demonstrating broad applicability in genome editing with reduced hepatotoxicity and off-target effects.
Smart Images

Figure PCTCN2026097531-FTAPPB-I100001 
Figure PCTCN2026097531-FTAPPB-I100002 
Figure PCTCN2026097531-FTAPPB-I100003
Abstract
Description
RNA-guided DNA Binding Agent and its Delivery System
[0001] This application claims the priority to provisional patent application PCT / CN2025 / 095484, filed on 16 May 2025. The entire contents of this provisional application are hereby incorporated by reference.TECHNICAL FIELD
[0002] The present disclosure relates to an RNA-guided DNA binding agent and its delivery system for gene targeting and editing. BACKGROUND OF DISCLOUSURE
[0003] Virus-like particles (VLPs) have emerged as promising vehicles for delivering gene-editing tools due to their biocompatibility, efficient cellular uptake, and reduced immunogenicity compared to viral vectors. In the field of genome editing, VLPs are particularly advantageous for encapsulating and delivering ribonucleoprotein (RNP) complexes, such as Cas9 nuclease paired with single-guide RNA (sgRNA) , to target cells. This approach minimizes risks associated with DNA-based delivery, such as genomic integration, while enabling transient yet potent editing activity. Recent advancements have demonstrated the utility of VLPs in delivering CRISPR-Cas9 systems, exemplified by engineered eVLPs that co-package Cas9-sgRNA RNPs, enhancing precision and reducing off-target effects.
[0004] However, despite their potential, current VLP platforms face significant limitations in delivering Cas proteins. A major challenge lies in poor compatibility with many Cas orthologs or engineered variants. Structural and size constraints of VLPs often restrict efficient packaging of larger or structurally divergent Cas proteins, limiting their versatility. Furthermore, Cas9-dependent VLPs are constrained by the protospacer adjacent motif (PAM) requirements of the incorporated nuclease. For instance, Streptococcus pyogenes Cas9 (SpCas9) , commonly used in VLP systems, recognizes a narrow NGG PAM sequence, reducing the range of targetable genomic sites. This limitation hinders applications requiring alternative PAM specificities. These shortcomings underscore the need for innovative VLP engineering strategies to improve compatibility with diverse Cas proteins and expand PAM flexibility. Current approaches often fail to address these dual challenges, leaving unmet demands in therapeutic and research contexts where precise, adaptable delivery systems are critical.
[0005] The present disclosure seeks to overcome these limitations by redesigning VLP architectures and optimizing cargo-loading mechanisms, thereby enabling efficient delivery of a wider spectrum of Cas nucleases and broadening their applicability in genome editing. SUMMARY OF DISCLOSURE
[0006] In one aspect, this disclosure provides an RNA-guided DNA binding agent, comprising an amino acid sequence selected from: (i) a sequence of SEQ ID NO: 1; or (ii) a sequence having at least 90%sequence identity to SEQ ID NO: 1.
[0007] In some embodiment, the RNA-guided DNA binding agent is a nickase capable of cleaving one strand of a target DNA. In some embodiments, said agent is a dead RNA-guided DNA binding agent that binds target DNA without cleaving a target DNA. In some embodiments, the target DNA is selected from a double-stranded DNA, a single-stranded DNA, or both.
[0008] In some embodiments, the amino acid sequence of the RNA-guided DNA binding agent comprises one or more mutations in an HNH domain and / or a RuvC domain relative to SEQ ID NO: 1. In some embodiments, said one or more mutations result in a loss of DNA cleavage activity in the HNH domain, the RuvC domain, or both.
[0009] In some embodiments, said one or more mutations comprise an amino acid substitution at a position corresponding to residue 11, and / or 587 of SEQ ID NO: 1. In some embodiments, said one or more mutations are selected from the group consisting of D11A and H587A, wherein each mutation is at a position corresponding to that of SEQ ID NO: 1. In some embodiments, the RNA-guided DNA binding agent retains the RNA-guided DNA binding activity.
[0010] In some embodiments, the RNA-guided DNA binding agent recognizes a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .
[0011] In some embodiments, the RNA-guided DNA binding agent comprises a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to any one of SEQ ID NOs: 201-203.
[0012] In another aspect, this disclosure provides a polynucleotide encoding the RNA-guided DNA binding agent as described herein.
[0013] In yet another aspect, this disclosure provides a chimeric polypeptide comprising the RNA-guided DNA binding agent as described herein and an effector domain. In some embodiments, the effector domain comprises sequences selected from the group consisting of: a nuclear localization signal sequence, a nuclear export signal sequence, a cell-penetrating peptide sequence, an affinity tag sequence, a deaminase sequence, a reverse transcriptase sequence, a recombinase sequence, a methyltransferase sequence, a methylase sequence, an acetylase sequence, an acetyltransferase sequence, a transcriptional activator sequence, a transcriptional repressor domain sequence, a cryptochrome sequence, a light inducible / controllable domain sequence, a chemically inducible / controllable domain sequence, and a replication initiation protein sequence.
[0014] In some embodiments, the chimeric polypeptide further comprises one or more NLSs. In some embodiments, the fusion protein comprises 1-7 NLSs. In some embodiments, the chimeric polypeptide comprises 3-6 NLSs. In some embodiments, the chimeric polypeptide comprises 1, 2, 3, 4, 5, 6, or 7 NLS (s) . In some embodiments, the chimeric polypeptide comprises at least one NLS at N-terminus. In some embodiments, the chimeric polypeptide comprises at least one NLS at C-terminus. In some embodiments, the chimeric polypeptide comprises at least one NLS at N-terminus and at least one NLS at C-terminus.
[0015] In some embodiments, the chimeric polypeptide comprises an amino acid sequence selected from: (i) a sequence of SEQ ID NO: 222 or SEQ ID NO 24; or (ii) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 222 or SEQ ID NO 24.
[0016] In another aspect, this disclosure provides a virus-like particle (VLP) . In some embodiments, the VLP comprises an envelope and a core.
[0017] In some embodiments, the VLP comprises on its surface: (a) a glycoprotein derived from BaEV; and (b) a CD58 extracellular domain sequence, a CD80 or CD86 extracellular domain sequence, an anti-CD3 antibody or antigen-binding fragment, or a combination thereof.
[0018] In some embodiments, the virus-like particle comprises: (a) an envelope comprising an envelope glycoprotein; (b) a group-specific antigen (Gag) -polymerase (pol) polyprotein; (c) a fusion protein comprising a Gag polypeptide, an RNA-guided DNA binding agent as described in this disclosure and a cleavable linker; and (d) a guide RNA (gRNA) capable of binding to a target DNA sequence.
[0019] In some embodiments, the virus-like particle comprises: (a) an envelope comprising an envelope glycoprotein; (b) a group-specific antigen (Gag) -polymerase (pol) polyprotein; (c) a fusion protein comprising a Gag polypeptide; (d) an RNA-guided DNA binding agent as described in this disclosure; and (e) a guide RNA (gRNA) .
[0020] In some embodiments, the Gag polypeptide and the RNA-guided DNA binding agent were fused via a cleavable linker located therebetween to form a fusion protein, and the cleavable linker has subsequently been cleaved by the protease of the Gag-pol polyprotein.
[0021] In some embodiments, the fusion protein further comprises: a nuclear export sequence (NES) . In some embodiments, the fusion protein comprises two NESs, three NESs, four NESs, five NESs, six NESs, seven NESs, eight NESs, nine NESs, or ten NESs; preferably, the fusion protein comprises four NESs. In some embodiments, the cleavable linker is located between the RNA-guided DNA binding agent and the NES (s) .
[0022] In some embodiments, the cleavable linker comprises a protease cleavage site. In some embodiments, the protease cleavage site is a Moloney murine leukemia virus (MMLV) protease cleavage site or a Friend murine leukemia virus (FMLV) protease cleavage site.
[0023] In some embodiments, the fusion protein further comprises a nuclear localization sequence (NLS) . In some embodiments, the fusion protein further comprises two NLSs, three NLSs, four NLSs, or five NLSs. Preferably, the fusion protein comprises two NLSs.
[0024] In some embodiments, the gag-pol polyprotein is an MMLV Gag-pol polyprotein or an FMLV Gag-pol polyprotein.
[0025] In some embodiments, the fusion protein comprises the structure: [gag polypeptide] - [2X-5X NESs] - [cleavable linker] - [NLS (s) ] - [RNA-guided DNA binding agent] - [NLS (s) ] ; optionally, the “] - [” comprises a linker; In some embodiments, the fusion protein comprises the structure: [Gag polypeptide] - [2X-5X NES] - [cleavable linker] - [NLS (s) ] - [Cas9] - [NLS (s) ] ; optionally the “] - [” comprises a linker.
[0026] In some embodiments, the Gag polypeptide comprises a capsid (CA) polypeptide and / or a matrix (MA) polypeptide. In some embodiments, the Gag polypeptide is selected from the group consisting of: a Moloney murine leukemia virus-derived structural protein, a Bovine immunodeficiency virus-derived structural protein, a Simian immunodeficiency virus-derived structural protein, a Feline immunodeficiency virus-derived structural protein, a Human immunodeficiency virus-derived structural protein, Equine infection anemia virus-derived structural protein, a Caprine arthritis encephalitis virus-derived structural protein, a Baboon endogenous virus-derived structural protein, and an endogenous retrovirus (HERV) derived structural protein.
[0027] In some embodiments, the Gag polypeptide is selected from the group consist of:Moloney murine leukemia virus (MMLV) -derived Gag polypeptide, and HIV-1 derived Gag polypeptide.
[0028] In some embodiments, the Gag polypeptide is a chimeric Gag. In some embodiments, the chimeric Gag comprises: (a) a core-assembly domain selected from: (i) a capsid (CA) domain derived from a structural protein of a first virus, or a functional fragment thereof; and (ii) a capsid (CA) -like domain derived from a first endogenous structural protein, or a functional fragment thereof; and (b) a membrane recruitment domain that is heterologous with the domain of (a) .
[0029] In some embodiments, the first virus is a first Retroviridae virus; optionally, the first Retroviridae virus is selected from Reticuloendotheliosis virus (REV) , Rous sarcoma virus (RSV) , Avian leukosis virus (ALV) , Murine leukemia virus (MLV) , Feline leukemia virus (FeLV) , Bovine leukemia virus (BLV) , Gibbon ape leukemia virus (GaLV) , and Human immunodeficiency virus type 1 (HIV-1) .
[0030] In some embodiments, the first endogenous structural protein is a human endogenous structural protein or animal endogenous structural protein; optionally, the first endogenous structural protein is selected from: ARC, PEG10, PNMA2, HERV-Kcon Gag, Arcl, Asprvl, PNMA1, PNMA3, PNMA4, PNMA5, PNMA6, PNMA7, RTL1, MOAPI, and ZCCHC12. In some embodiments, the membrane recruitment domain comprises a domain selected from: (a) a matrix (MA) domain derived from a structural protein of a second virus, or a functional fragment thereof; (b) a matrix (MA) -like domain derived from a second endogenous structural protein, or a functional fragment thereof.
[0031] In some embodiments, the second virus is selected from: Human Immunodeficiency Virus, Human T-lymphotropic virus, Bovine leukemia virus, Murine leukemia virus, Simian immunodeficiency virus, Feline leukemia virus, Avian leukosis virus, Rat leukemia virus, and Moloney Murine Leukemia Virus; preferably, the second virus is Moloney Murine Leukemia Virus.
[0032] In some embodiments, the second endogenous structural protein is selected from: ARC, PEG10, PNMA2, HERV-Kcon Gag, Arcl, Asprvl, PNMA1, PNMA3, PNMA4, PNMA5, PNMA6, PNMA7, RTL1, MOAPI, and ZCCHC12.
[0033] In some embodiments, the envelope glycoprotein is derived from virus selected from a group consisting of: Vesicular Stomatitis Virus (VSV) , Rabies virus (RABV) , Eastern equine encephalitis virus (EEEV) , Mokola virus (MOKV) , Lymphocytic choriomeningitis virus (LCMV) , Hepatitis B virus (HBV) , Chandipura virus (CNV / CHPV) , Baboon endogenous virus (BaEV) , Zika Virus, GP64 and Baculovirus.
[0034] In some embodiments, envelope glycoprotein is selected from: a vesicular stomatitis virus glycoprotein (VSV-G) , a measles virus hemagglutinin (HA) and / or fusion (F) glycoprotein, an influenza virus hemagglutinin (HA) and / or neuraminidase (NA) , a cocal virus glycoprotein, a Moloney murine leukemia virus (MMLV) envelope protein, a baboon endogenous retrovirus (BaEV) envelope protein, an Ebola virus glycoprotein, a Marburg virus glycoprotein, a foamy virus envelope protein, a hepatitis B virus (HBV) glycoprotein, a hepatitis C virus (HCV) glycoprotein, a SARS coronavirus (SARS-CoV) glycoprotein, a respiratory syncytial virus (RSV) glycoprotein, a human parainfluenza virus glycoprotein, a human T-cell lymphotropic virus type 1 (HTLV-1) glycoprotein, a Ross River virus glycoprotein, a rabies virus glycoprotein, a Mokola virus glycoprotein, a Semliki Forest virus glycoprotein, a Sindbis virus glycoprotein, a Venezuelan equine encephalitis virus glycoprotein, a Sendai virus glycoprotein, a baculovirus envelope glycoprotein (e.g., GP64) , an Eastern equine encephalitis virus (EEEV) glycoprotein, a Lymphocytic choriomeningitis virus (LCMV) glycoprotein, a Chandipura virus (CHPV) glycoprotein, a Zika virus envelope protein or any variants thereof retaining membrane fusion properties. In some embodiments, the variant of the glycoprotein comprises at least one of: (a) one or more amino acid substitutions that reduce binding of the viral envelope protein to its natural receptor; (b) deletion of a functional domain; or (c) fusion with a heterologous functional domain. In some embodiments, the envelope glycoprotein is a variant viral envelope protein that comprises one or more amino acid modifications selected from substitutions, deletions, insertions, and / or truncations, which reduce binding of the viral envelope protein to its receptor and retaining membrane fusion properties.
[0035] In some embodiments, the VLP further comprises a targeting polypeptide. In some embodiments, the targeting polypeptide comprises one or more antibodies or antibody analogs. In some embodiments, the one or more antibody analogs is an affibody, an affilin, an affimer, an affitin, an alphabody, an anticalin, an avimer, a DARPin, a Fynomer, a Kunitz domain peptide, a monobody, a repebody, a VLR, or a nanoCLAMP. In some embodiments, the targeting polypeptide is selected from: single chain variable fragment (scFv) , nanobody, multidomain fusion protein (MDF) .
[0036] In some embodiments, the gRNA binds to the RNA-guided DNA binding agent. In some embodiments, the gRNA is a dual guide RNA. In some embodiments, the gRNA is a single guide RNA (sgRNA) . In some embodiments, the sgRNA comprises: (a) a scaffold sequence selected from any one of SEQ ID NOs: 7-8; (b) a scaffold sequence having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, or at least 90%identity to any one of SEQ ID NOs: 7-8.
[0037] In some embodiments, the Gag polypeptide comprises a capsid (CA) polypeptide and / or a matrix (MA) polypeptide. In some embodiments, the Gag polypeptide is selected from the group consisting of: a Moloney murine leukemia virus-derived structural protein, a Bovine immunodeficiency virus-derived structural protein, a Simian immunodeficiency virus-derived structural protein, a Feline immunodeficiency virus-derived structural protein, a Human immunodeficiency virus-derived structural protein, Equine infection anemia virus-derived structural protein, a Caprine arthritis encephalitis virus-derived structural protein, a Baboon endogenous virus-derived structural protein, and an endogenous retrovirus (HERV) derived structural protein.
[0038] In some embodiments, the Gag polypeptide is selected from the group consist of: Moloney murine leukemia virus (MMLV) -derived Gag polypeptide, and HIV-1 derived Gag polypeptide.
[0039] In some embodiments, the envelope glycoprotein is derived from virus selected from a group consisting of: Vesicular Stomatitis Virus (VSV) , Rabies virus (RABV) , Eastern equine encephalitis virus (EEEV) , Mokola virus (MOKV) , Lymphocytic choriomeningitis virus (LCMV) , Hepatitis B virus (HBV) , Chandipura virus (CNV / CHPV) , Baboon endogenous virus (BaEV) , Zika Virus, GP64 and Baculovirus.
[0040] In some embodiments, the gRNA binds to the RNA-guided DNA binding agent. In some embodiments, wherein the gRNA is a dual guide RNA or a single guide RNA (sgRNA) , preferably, the gRNA is a sgRNA. In some embodiments, the sgRNA comprises: (a) a scaffold sequence selected from any one of SEQ ID NOs: 7-8; (b) a scaffold sequence having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, or at least 90%identity to any one of SEQ ID NOs: 7-8. In some embodiments, the gRNA comprises a spacer sequence, and the spacer sequence (a) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (b) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (c) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148.
[0041] In another aspect, this disclosure provides a plurality of polynucleotides comprising: (i) a first polynucleotide comprising a nucleic acid sequence encoding an envelope glycoprotein as described in this disclosure; (ii) a second polynucleotide comprising a nucleic acid sequence encoding a fusion protein as described in this disclosure; (iii) a third polynucleotide comprising a nucleic acid sequence encoding a Gag-pol polyprotein as described in this disclosure; (iv) a fourth polynucleotide comprising a nucleic acid sequence encoding a gRNA as described in this disclosure.
[0042] In yet another aspect, this disclosure provides a guide RNA or a polynucleotide encoding such guide RNA, wherein the guide RNA comprising (a) a spacer sequence: (i) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (ii) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (iii) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; and (b) a binding segment capable of binding to RNA-guided DNA binding agent as described herein; wherein the binding segment comprises a tracrRNA sequence and a direct repeat (DR) sequence that hybridizes to form a double-stranded RNA (dsRNA) duplex.
[0043] In some embodiments, the gRNA is a dual guide RNA or a single guide RNA. In some embodiments, the sgRNA comprises: (a) a scaffold sequence selected from any one of SEQ ID NOs: 7-8; or (b) a scaffold sequence having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, or at least 90%identity to any one of SEQ ID NOs: 7-8.
[0044] In some embodiments, at least three nucleotides of the gRNA are modified.
[0045] In yet another aspect, this disclosure provides a guide RNA or a polynucleotide encoding such guide RNA, wherein the guide RNA comprising a binding segment capable of binding to RNA-guided DNA binding agent as described herein; wherein the binding segment comprises a tracrRNA sequence and a direct repeat (DR) sequence that hybridizes to form a double-stranded RNA (dsRNA) duplex.
[0046] In some embodiments, the gRNA is a dual guide RNA or a single guide RNA.
[0047] In some embodiments, the sgRNA comprises: (a) a scaffold sequence selected from any one of SEQ ID NOs: 7-8; or (b) a scaffold sequence having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, or at least 90%identity to any one of SEQ ID NOs: 7-8.
[0048] In some embodiments, the sgRNA comprises: a spacer sequence, wherein the spacer sequence: (i) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (ii) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (iii) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148.
[0049] In some embodiments, at least three nucleotides of the gRNA are modified.
[0050] In yet another aspect, this disclosure provides an engineered, non-naturally occurring CRISPR / Cas system comprising: (a) an RNA-guided DNA binding agent as described in this disclosure or a polynucleotide encoding such RNA-guided DNA binding agent; and (b) at least one guide RNA (gRNA) as described in this disclosure or at least one engineered polynucleotide encoding such gRNA, wherein said gRNA comprises a spacer sequence that is complementary to a target nucleic acid.
[0051] In some embodiments, the CRISPR / Cas system further comprises a donor template nucleic acid. In some embodiments, the donor template nucleic acid is a double-stranded nucleic acid. In some embodiments, the donor template nucleic acid is a single-stranded nucleic acid. In some embodiments, the donor template nucleic acid is linear. In some embodiments, the donor template nucleic acid is circular. In some embodiments, the donor template nucleic acid is an exogenous nucleic acid molecule. In some embodiments, the donor template nucleic acid is an endogenous nucleic acid molecule.
[0052] In yet another aspect, this disclosure provides one or more vectors comprising the plurality of polynucleotides as described herein.
[0053] In some embodiments, each of the first, second, third, and fourth polynucleotides are on the separate vectors. In some embodiments, two or more of the first, the second, third, and fourth polynucleotides are on the same vector.
[0054] In one aspect, this disclosure also provides a cell comprising: (a) the virus-like particle as described in this disclosure; (b) the plurality of polynucleotides as described in this disclosure; or (c) one or more vectors as described in this disclosure.
[0055] In one aspect, this disclosure also provides a method of making a virus-like particle, comprising transfecting the plurality of polynucleotides as described in this disclosure, or the one or more vectors as described in this disclosure into a cell and expressing the components of the virus-like particle from the plurality of polynucleotides or one or more vectors in the cell, thereby allowing the virus-like particle to spontaneously assemble in the cell.
[0056] In one aspect, this disclosure also provides a pharmaceutical composition comprising the virus-like particle as described herein, the RNA-guided DNA binding agent as described herein, the polynucleotide encoding RNA-guided DNA binding agent as described herein, the gRNA as described herein, the polynucleotide encoding the gRNA as described herein, or the CRISPR / Cas system as described herein.
[0057] In one aspect, this disclosure provides a kit comprising the virus-like particle as described herein, the RNA-guided DNA binding agent as described herein, the polynucleotide encoding RNA-guided DNA binding agent as described herein, the gRNA as described herein, the polynucleotide encoding the gRNA as described herein, the plurality of polynucleotides as described herein, one or more vectors as described herein, or the pharmaceutical composition as described herein.
[0058] In one aspect, this disclosure provides a method of editing a nucleic acid molecule in a target cell comprising contacting the target cell with the virus-like particle as described herein, the RNA-guided DNA binding agent as described herein, the polynucleotide encoding RNA-guided DNA binding agent as described herein, the gRNA as described herein, the polynucleotide encoding the gRNA as described herein, the CRISPR / Cas system as described herein, or the pharmaceutical composition as described herein, thereby installing one or more modifications to the nucleic acid molecule at a target site.
[0059] In some embodiments, the modification comprises (a) a DNA strand break selected from the group consisting of a DNA double-strand break (DSB) and a DNA single-strand break (SSB) ; (b) an alteration in the expression of one or more genes; or (c) an epigenetic modification of the target DNA locus.
[0060] In some embodiments, the method as described in this disclosure is ex vivo or in vivo.
[0061] In one aspect, this disclosure provides use of the virus-like particle as described herein, the RNA-guided DNA binding agent as described herein, the polynucleotide encoding RNA-guided DNA binding agent as described herein, the gRNA as described herein, the polynucleotide encoding the gRNA as described herein, the CRISPR / Cas system as described herein, or the pharmaceutical composition as described herein, in treating a disorder, comprising editing a target gene.
[0062] In some embodiments, the target gene comprises a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .
[0063] In one aspect, this disclosure provides a method for treating a disorder in a subject, comprising: administering to the subject the virus-like particle as described herein, the RNA-guided DNA binding agent as described herein, the polynucleotide encoding RNA-guided DNA binding agent as described herein, the gRNA as described herein, the polynucleotide encoding the gRNA as described herein, the CRISPR / Cas system as described herein, or the pharmaceutical composition as described herein.
[0064] In some embodiments, the virus-like particle, the RNA-guided DNA binding agent, the polynucleotide encoding RNA-guided DNA binding agent, the gRNA, the polynucleotide encoding the gRNA, the CRISPR / Cas system, or the pharmaceutical composition is capable of editing a target gene in the subject, or participating in the editing thereof.
[0065] In some embodiments, the target gene comprises a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .
[0066] In one aspect, this disclosure also provides a use of a CRISPR / Cas system as described herein or the RNA-guided DNA binding agent as described herein, in recognizing a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .
[0067] In one aspect, this disclosure also provides use of a CRISPR / Cas system as described herein, the virus-like particle as described herein, the RNA-guided DNA binding agent as described herein, the polynucleotide encoding RNA-guided DNA binding agent herein, the gRNA as described herein, or the polynucleotide encoding the gRNA as described herein, in the manufacture of a medicament for treating a disorder.
[0068] Beneficial effects of the present application: The present application provides an RNA-guided DNA binding agent, and its delivering system for gene targeting and editing. The CRISPR system as described herein targets non-canonical PAM sequences. The RNA-guided DNA binding agent disclosed herein are highly compatible with VLP delivery systems. And the present application can achieve the technical effects of efficient delivery of a wider spectrum of Cas protein, minimal off-target activity, high gene editing efficiency, and broader applicability in genome editing. Additionally, the present application can achieve a high editing efficiency in liver with minimal off-target effects in other tissues and no detectable hepatotoxicity. BRIEF DESCRIPTION OF FIGURES
[0069] An understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure may be utilized, and the accompanying drawings of which:
[0070] Figure 1 (FIG. 1) shows the modeling structure of GEBx0321-sgRNA-PT-V1 scaffold RNP (A) , and GEBx0321-sgRNA-PT-V2 scaffold RNP (B) .
[0071] Figure 2 (FIG. 2) shows the domain arrangement of GEBx0321.
[0072] Figure 3 (FIG. 3) shows the PAM preference of GEBx0321 in HEK293T cell line.
[0073] Figure 4 (FIG. 4) shows GEBx0321 editing activity at the human endogenous genes in HEK293T cell using plasmid delivery.
[0074] Figure 5 (FIG. 5) shows GEBx0321 editing activity at the human endogenous genes in HEK293 cell using VLP delivery
[0075] Figure 6 (FIG. 6) shows the comparison of indel editing efficiencies of GEBx0321 and GEBx0305 delivered or transfected by VLP and lipoplex. Data for GEBx0321 shown in the figure were obtained from its editing results at the CFTR-NNNNCAAA-sg-5 / 7, POLQ-NNNNCAAA-sg-1 / 2, and RNF2-NNNNCAAA-sg7 target sites.
[0076] Figure 7 (FIG. 7) shows off-target effects at the tested endogenous loci editing by GEBx0321 using plasmid or VLP delivery.
[0077] Figure 8 (FIG. 8) shows guide RNA screening of the GEBx0321-VLP in Hepa1-6 cells.
[0078] Figure 9 (FIG. 9) shows in vitro dose-response efficacy of GEBx0321-VLP in Hepa1-6 cells.
[0079] Figure 10 (FIG. 10) shows biodistribution of the GEBx0321-VLP via systemic delivery, represented by the editing efficiencies at the mTTR gene of corresponding organs.
[0080] Figure 11 (FIG. 11) shows transient liver toxicity of the GEBx0321-VLP after systemic administration.
[0081] Figure 12 (FIG. 12) shows gRNA screening of the GEBx0321-VLP in HCE-T cells.
[0082] Figure 13 (FIG. 13) shows the editing efficiency by GEBx0321 at CD3ε.
[0083] Figure 14 (FIG. 14) shows the effect of guide RNA spacer length on perfect-match vs. off-target (mismatch) detection for the HPA-Humanspacer3 target.
[0084] Figure 15 (FIG. 15) shows the effect of guide RNA spacer length on editing efficiency at three endogenous human loci.
[0085] Figure 16 (FIG. 16) shows the validation of GEBx0321-nickase activity with dual sgRNAs GEBx0321-sg1 / sg2 in HEK293T cell.
[0086] Figure 17 (FIG. 17) shows the validation of GEBx0321-nickase activity with dual sgRNAs GEBx0321-sg3 / sg4 in HEK293T cells.
[0087] Figure 18 (FIG. 18) shows the GEBx0321-ABE-mediated A-to-G Editing using VLP delivery system.DETAILED DESCRIPTION
[0088] The following examples further illustrate the present disclosure, but the present disclosure is not limited thereto.
[0089] The present disclosure provides a virus-like particle (VLP) .
[0090] As used in this disclosure, the virus-like particle (VLP) means a non-replicative, self-assembling macromolecular complex that mimics the structure of a natural virus particle but lacks infectious viral genetic material. The terms “VLP” and “PDV” (protein delivery vehicle) are used interchangeably herein.
[0091] Typically, the VLP is produced by co-expressing the self-assembling components in a suitable host cell (e.g., a mammalian or insect cell) , wherein the Gag and / or Gag-Pol polyproteins self-assemble at the plasma membrane and bud off as particle structures encapsulating the cargo.
[0092] In some embodiments, the Gag component and / or the Gag portion of the Gag-Pol polyprotein may be of viral or endogenous origin. In some embodiments, the Gag and / or the Gag portion of the Gag-Pol may be chimeric, comprising heterologous subunits (achimeric Gag) . In some embodiments, the Gag and / or the Gag portion of the Gag-Pol may comprise only selected functional domains or subunits thereof, such as CA (capsid) , MA (matrix) , NC (nucleocapsid) , or combinations thereof. In some embodiments, the Gag and / or the Gag portion of the Gag-Pol may comprise only fragments of such domains or subunits. In some embodiments, the subunits may be of viral or endogenous origin. In some embodiments, the Pol portion of the Gag-Pol polyprotein may similarly comprise only selected functional domains or subunits thereof, such as a protease domain (PR) , reverse transcriptase (RT) , integrase (IN) , or RNase H, or combinations thereof. In some embodiments, the Pol may comprise only fragments of such domains or subunits.
[0093] It is noted that, unless otherwise indicated or clearly contradicted by context, any description in this disclosure referring to “Gag” shall be understood to apply independently and to the Gag portion of a Gag-Pol polyprotein, as well as to the Gag portion of a fusion protein comprising Gag and an RNA-guided DNA binding agent. It is further noted that the Gag polypeptide and the Gag portion of a Gag-Pol polyprotein, and the Gag portion of a fusion protein with an RNA-guided DNA binding agent may be identical or different in sequence.
[0094] In some embodiments, the Gag and / or the Gag portion of the Gag-Pol are derived from a Retroviridae virus selected from: Reticuloendotheliosis virus (REV) , Rous sarcoma virus (RSV) , Avian leukosis virus (ALV) , Murine leukemia virus (MLV) , Simian immunodeficiency virus, Feline leukemia virus (FeLV) , Bovine leukemia virus (BLV) , Gibbon ape leukemia virus (GaLV) , and Human immunodeficiency virus type 1 (HIV-1) . In some embodiments, Gag and / or the Gag portion of the Gag-Pol are derived from Equine infectious anemia virus, Caprine arthritis encephalitis virus, Baboon endogenous virus. In some embodiments, the Gag and / or the Gag portion of the Gag-Pol are derived from a human endogenous retrovirus (HERV) .
[0095] In some embodiment, the chimeric Gag comprises: (a) a core-assembly domain selected from: (i) a capsid (CA) domain derived from a structural protein of a first virus, or a functional fragment thereof; and (ii) a capsid (CA) -like domain derived from a first endogenous structural protein, or a functional fragment thereof; and (b) a membrane recruitment domain that is heterologous with the domain of (a) .
[0096] As used in this disclosure, a “capsid-like domain” or “CA-like domain” refers to a protein domain whose folding pattern or overall structure resembles that of a viral capsid protein. In some embodiments, a “capsid-like domain” may indicate one of the following scenarios: (i) Structural Resemblance: A protein domain may be termed “capsid-like” if its folding pattern closely mirrors that of a portion of a viral capsid protein. (ii) Functional Similarity: In some cases, a protein domain may not only share structural resemblance with a viral capsid protein but also exhibit similar functional properties, such as the ability to form multimers or participate in some form of assembly. (iii) Evolutionary Relationship: Sometimes, “capsid-like domain” may imply an evolutionary connection between the domain and viral capsid proteins, suggesting they might have descended from a common ancestral protein. In some specific embodiment, the capsid-like domain exhibits self-assembly activity functionally analogous to a viral capsid protein, regardless of structural homology.
[0097] In some embodiments, the first virus is a first Retroviridae virus; optionally, the first Retroviridae virus is selected from Reticuloendotheliosis virus (REV) , Rous sarcoma virus (RSV) , Avian leukosis virus (ALV) , Murine leukemia virus (MLV) , Feline leukemia virus (FeLV) , Bovine leukemia virus (BLV) , Gibbon ape leukemia virus (GaLV) , and Human immunodeficiency virus type 1 (HIV-1) .
[0098] In some embodiments, the first virus is a first non-Retroviridae virus; optionally, the first non-Retroviridae virus is selected from: Flaviviridae, Togaviridae, Coronaviridae, Parvoviridae, Adenoviridae, Herpesviridae, Papovaviridae, Hepadnaviridae, Polyomaviridae, Asfarviridae, Reoviridae, Birnaviridae, Orthomyxovirida, Bunyaviridae, Rhabdoviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, Astroviridae, Circoviridae, Hepeviridae, Picornaviridae, and Caliciviridae.
[0099] In some embodiments, the first endogenous structural protein is a human endogenous structural protein or animal endogenous structural protein; optionally, the first endogenous structural protein is selected from: ARC, PEG10, PNMA2, HERV-Kcon Gag, Arcl, Asprvl, PNMA1, PNMA3, PNMA4, PNMA5, PNMA6, PNMA7, RTL1, MOAPI, and ZCCHC12.
[0100] In some embodiments, the functional fragment of the first capsid (CA) domain or the first capsid (CA) -like domain is selected from: a C-terminal domain (CTD) , an N-terminal domain (NTD) or a charged assembly helix (CAH) of said CA domain or CA-like domain. In some embodiments, the fragment of the first capsid (CA) domain does not comprise a N-terminal domain (NTD) domain.
[0101] In some embodiments, the membrane recruitment domain comprises a domain selected from: (a) a matrix (MA) domain derived from a structural protein of a second virus, or a functional fragment thereof; (b) a matrix (MA) -like domain derived from a second endogenous structural protein, or a functional fragment thereof.
[0102] As used in this disclosure, “amembrane recruitment domain” refers to a specific class of protein domains whose primary role is to recognize or, after self-modification, recognize and bind to specific lipids, ligands, signal sequences, or proteins on the cell membrane, or to aid intracellular components (such as proteins) in recognizing and binding to specific lipids, ligands, or proteins on the cell membrane, thereby recruiting the entire protein complex to the cell membrane. For example, the PH domain (Pleckstrin homology domain) is a common type of membrane recruitment domain that can recognize and bind to phosphoinositides on the cell membrane. In some embodiments, a membrane recruitment domain may be characterized by a functional capability such as: (i) Electrostatic or hydrophobic interactions with specific lipids (e.g., anionic phospholipids, acyl chains) , (ii) Binding to membrane-associated proteins (e.g., receptors, scaffolds) , or (iii) Lipidation-dependent anchoring (e.g., myristoylation, palmitoylation, prenylation, GPI) . In some embodiments, this domain may be characterized by structural features such as: (i) Basic residue clusters (e.g., poly-K / R motifs) , (ii) Lipid-binding folds (e.g., PH, C1, C2, FYVE, BAR) , or (iii) Intrinsically disordered regions capable of phase separation, curvature sensing or ligand docking. The membrane recruitment domain mediates association with lipid bilayers through electrostatic or hydrophobic interactions and / or covalent lipid anchoring, and (ii) further promotes assembly or maturation of an engineered VLP. In the exemplary embodiments, the membrane recruitment domain is a retroviral Matrix (MA) domain selected from the group consisting of: (a) Moloney murine leukemia virus (MMLV) MA domain; (b) Human immunodeficiency virus type-1 (HIV-1) MA domain; and (c) functional fragments or variants thereof that retain both membrane-binding activity and VLP assembly-promoting activity. In some other exemplary embodiments, the PH domain is a common membrane recruitment domain that binds phosphoinositides.
[0103] As used in this disclosure, “matrix-like domain” refers to a protein domain that exhibits significant structural, functional, or evolutionary similarity to a viral Matrix protein (MA) . This domain may display characteristics such as: (a) structural similarity: the domain possesses a folding pattern or spatial configuration that closely resembles that of a viral Matrix protein, potentially including similar secondary structures like alpha-helices and beta-sheets arrangements, or analogous tertiary structures; (b) functional similarity: The domain may carry out biological functions akin to those of a viral Matrix protein, such as participating in protein-protein interactions, facilitating virus assembly and budding; (c) evolutionary relationship: The domain could share an evolutionary lineage with viral Matrix proteins, suggesting a common ancestral origin and implying homology between the two.
[0104] In some embodiments, the second virus is a second Retroviridae virus; optionally, the second Retroviridae virus is selected from: Human Immunodeficiency Virus, Human T-lymphotropic virus, Bovine leukemia virus, Murine leukemia virus, Simian immunodeficiency virus, Feline leukemia virus, Avian leukosis virus, Rat leukemia virus, and Moloney Murine Leukemia Virus; preferably, the Retroviridae virus is Moloney Murine Leukemia Virus.
[0105] In some embodiments, the second virus is a second non-Retroviridae virus, optionally, the second non-Retroviral virus is selected from: Orthomyxoviridae, Bunyaviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, Coronaviridae, Flaviviridae, Togaviridae, Rhabdoviridae, Caliciviridae, Reoviridae, Binaviridae, Papillomaviridae, Polyomaviridae, Parvoviridae, Adenoviridae, Herpesviridae, Hepadnaviridae, Fimoviridae and Astroviridae, Circoviridae, Hepeviridae, Parvoviridae, Picornaviridae, Matonaviridae.
[0106] In some embodiments, the second endogenous structural protein is selected from: ARC, PEG10, PNMA2, HERV-Kcon Gag, Arcl, Asprvl, PNMA1, PNMA3, PNMA4, PNMA5, PNMA6, PNMA7, RTL1, MOAPI, and ZCCHC12.
[0107] In some embodiments, the membrane recruitment domain comprises a Pleckstrin homology (PH) domain; optionally, the Pleckstrin homology (PH) domain is selected from the group consisting of Pleckstrin homology domain of Human Dappl, Pleckstrin homology domain of Mouse Grp1, Pleckstrin homology domain of Human Grp1, Pleckstrin homology domain of Human OSBP, Pleckstrin homology domain of Human Btk1, Pleckstrin homology domain of Human FAPP1, Pleckstrin homology domain of Human CERT, Pleckstrin homology domain of Human PKD, Pleckstrin homology domain of Human PHLPP1, Pleckstrin homology domain of Human SWAP70, Pleckstrin homology domain of Human MAPKAP1, Pleckstrin homology domain of Human phospholipase Cδ1 (hPLCδ1) , Pleckstrin homology domain of human Akt1, Mutant Pleckstrin homology domain of human Akt1 (E17K) , or Pleckstrin homology domain of human phossephoinositede-dependent protein kinase 1 (Hpdpk1) .
[0108] In some exemplary embodiments, the Gag comprises a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 137 or SEQ ID NO: 138, as listed in Table 14.
[0109] In some embodiments, the fusion protein comprising Gag and an RNA-guided DNA binding agent comprises a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 132 or SEQ ID NO: 133, as listed in Table 14.
[0110] In some embodiments, the Gag-pol comprises a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 131 or SEQ ID NO: 136.
[0111] The VLP in this disclosure includes an envelope comprising an envelope glycoprotein (e.g., a viral envelope glycoprotein) . Suitable viral envelope proteins include, without limitation, a vesicular stomatitis virus glycoprotein (VSV-G) , a measles virus hemagglutinin (HA) and / or fusion (F) glycoprotein, an influenza virus hemagglutinin (HA) and / or neuraminidase (NA) , a cocal virus glycoprotein, a Moloney murine leukemia virus (MMLV) envelope protein (e.g., ecotropic MLV-E or amphotropic MLV-A) , a baboon endogenous retrovirus (BaEV) envelope protein, an Ebola virus glycoprotein, a Marburg virus glycoprotein, a foamy virus envelope protein, a hepatitis B virus (HBV) glycoprotein, a hepatitis C virus (HCV) glycoprotein, a SARS coronavirus (SARS-CoV) glycoprotein, a respiratory syncytial virus (RSV) glycoprotein, a human parainfluenza virus glycoprotein, a human T-cell lymphotropic virus type 1 (HTLV-1) glycoprotein, a Ross River virus glycoprotein, a rabies virus glycoprotein, a Mokola virus glycoprotein, a Semliki Forest virus glycoprotein, a Sindbis virus glycoprotein, a Venezuelan equine encephalitis virus glycoprotein, a Sendai virus glycoprotein, a baculovirus envelope glycoprotein (e.g., GP64) , an Eastern equine encephalitis virus (EEEV) glycoprotein, a Lymphocytic choriomeningitis virus (LCMV) glycoprotein, a Chandipura virus (CHPV) glycoprotein, a Zika virus envelope protein. In some embodiments, suitable viral envelope proteins include variants of any of the foregoing comprising one or more amino acid substitutions that reduce binding of the viral envelope protein to its natural receptor. In some embodiments, the viral envelope protein is selected from any one or more of the above-listed proteins. In some embodiments, the viral envelope protein is a combination of two or more of the foregoing. In some exemplary embodiments, the VSV-G encoding sequence is shown as SEQ ID NO: 140.
[0112] In some embodiments, the viral envelope protein is a variant that includes one or more amino acid substitutions that reduce binding of the viral envelope protein to its receptor.
[0113] In some embodiments, the viral envelope protein is a modified variant that exhibits reduced or abolished binding to its natural receptor and / or retained membrane fusion properties while retaining the capacity to mediate lipid bilayer fusion. Examples of such modifications may comprise: (i) one or more amino acid substitutions that attenuate receptor binding, exemplified by a vesicular stomatitis virus (VSV) glycoprotein (e.g., VSV-G R354A or analogous receptor-binding-attenuated variants) , a measles virus hemagglutinin (H protein) (e.g., Y481A / R533A or other blinded variants that eliminate SLAM / CD46 binding while preserving fusion triggering) , or an influenza virus hemagglutinin (e.g., headless HA variants or receptor-binding site mutations that abrogate sialic acid recognition) ; or (ii) deletion of a functional domain (such as the R peptide) or generation of a chimeric construct, exemplified by a baboon endogenous retrovirus (BaEV) envelope protein (e.g., BaEV-Rless or BaEV / RD114) , wherein such modifications enhance membrane fusion efficiency without necessarily altering receptor binding specificity. In some embodiments, the envelop protein is a variant vesicular stomatitis virus glycoprotein (VSVG) that comprises a K to Q substitution and an R to A substitution at amino acid positions corresponding to K47 (K47Q) and R354 (R354A) .
[0114] In some exemplary embodiments, the envelope protein comprises a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 139 or SEQ ID NO: 134.
[0115] In some embodiments, the modified envelope protein is fused to or otherwise associated with a heterologous targeting moiety selected from: an antibody, a nanobody, a single-chain variable fragment (scFv) , a receptor ligand, or an aptamer.
[0116] In some embodiments, a targeting moiety or a targeting polypeptide is displayed on the VLP surface independently of the envelope protein, thereby directing the VLP to a target cell bearing the cognate antigen or receptor. Targeting polypeptides suitable for the present disclosure include antibodies and antibody mimetics (also referred to as antibody analogs) . Suitable antibody mimetics include, without limitation: an affibody, an affilin, an affimer, an affitin, an alphabody, an anticalin, an avimer, a DARPin, a Fynomer, a Kunitz domain peptide, a monobody, a repebody, a variable lymphocyte receptor (VLR) , and a nanoCLAMP. Suitable antibodies include: a single-chain variable fragment (scFv) , a diabody, a triabody, and a nanobody (e.g., a VHH domain) . In some embodiments, the targeting polypeptide is an scFv. In some embodiments, the targeting polypeptide is a nanobody. In some embodiments, the targeting polypeptide is a bispecific antibody or a multispecific antibody. In some embodiments, the VLP comprises two or more distinct targeting polypeptides (e.g., a first targeting polypeptide and a second targeting polypeptide) , wherein the first targeting polypeptide specifically binds to a first target polypeptide on a target cell and the second targeting polypeptide specifically binds to a second target polypeptide on the same target cell, thereby conferring dual-targeting specificity. In some embodiments, the targeting polypeptides is a multidomain fusion protein (MDF) . In some embodiments, the MDF comprises: (a) an extracellular domain, or a functional fragment thereof; (b) an extracellular domain, or a functional fragment thereof; and (c) an antigen-binding fragment. In some embodiments, the MDF comprises: (a) a CD58 extracellular domain, or a functional fragment thereof; (b) a CD80 or CD86 extracellular domain, or a functional fragment thereof; and (c) an antigen-binding fragment of an anti-CD3 antibody. In some embodiments, the MDF further comprises a linker sequence between any two of the foregoing domains. In some embodiments, the MDF has a sequence of SEQ ID NO: 135.
[0117] This disclosure also provides an RNA-guided DNA binding agent. And in some embodiments, the cargo intended to be encapsulated in the VLP also comprises such RNA-guided DNA binding agent.
[0118] As presented in this disclosure, the “RNA-guided DNA binding agent” (also referred to as an “RNA-guided DNA binding protein” , a “Cas protein” or a “CRISPR-Cas effector protein” ) means a polypeptide or complex of polypeptides having RNA and DNA binding activity, or a DNA-binding subunit of such a complex, wherein the DNA binding activity is sequence-specific and / or depends on the sequence of the RNA. Exemplary RNA-guided DNA binding agents include Cas cleavases, nickases and inactivated forms ( “dCas DNA binding agents” or dead Cas) .
[0119] In some embodiment, the RNA-guided DNA binding agent is GEBx0321 or any variant thereof. The domain architecture of GEBx0321 is depicted in FIG. 2. GEBx0321 comprises RuvC domains, a BH (bridge helix) domain, a REC domain, an HNH domain, and a CTD (C-terminal domain) , wherein the RuvC domain contains three split RuvC sub-domains. The RuvC domain and the HNH domain each possess nuclease catalytic activity, together generating a double-strand break. In certain embodiments, one or more mutations are introduced into catalytic residues of the RuvC domain and / or the HNH domain to eliminate endonuclease cleavage activity. As a non-limiting example, substitution of a catalytic aspartate, glutamate, or histidine residue within the RuvC domain (e.g., a D-to-A mutation at a position corresponding to a catalytic aspartate) abolishes cleavage of one DNA strand, thereby converting GEBx0321 into a nickase that cleaves only the target strand. Likewise, substitution of a catalytic histidine or asparagine residue within the HNH domain (e.g., an H-to-A or N-to-A mutation) abolishes cleavage of another DNA strand, yielding a nickase that cleaves only the non-target strand. Combined mutation of catalytic residues in both the RuvC domain and the HNH domain produces a catalytically dead GEBx0321 (dGEBx0321) , which lacks double-strand endonuclease activity but retains RNA-guided DNA-binding ability. The sequence of GEBx0321 and its nickase and dead Cas variants are shown in Table 1.
[0120] As used in this disclosure, the term “GEBx” followed by a numerical suffix is employed as a generic code to refer to either nucleic acids or proteins. It is important to note that the use of an identical code for a nucleic acid and a protein, or derivatives thereof, does not imply that the substances represented by those codes are themselves identical. In other words, a code such as GEBx0321 (or GEBx-ns) may denote a specific nucleic acid sequence in one context and a distinct protein in another. Some embodiments may, however, illustrate a direct correspondence between a nucleic acid and a protein designated by the same or derived codes. Accordingly, the “GEBx” code serves as an indexing system for organizing and referencing the diverse biomolecules described in this disclosure, and the meaning of a given code is to be understood based on the context in which it appears. For the avoidance of doubt, when a numerical suffix is presented with or without leading zeros (e.g., “GEBx0321” and “GEBx321” ) , the codes are intended to refer to the same entity.
[0121] In some embodiments, the RNA-guided DNA binding agent comprises an amino acid sequence selected from: (i) a sequence of SEQ ID NO: 1; or (ii) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 1. In some embodiments, the RNA-guided DNA binding agent comprises an amino acid sequence selected from: (i) a sequence of SEQ ID NO: 1 lacking the N-terminal methionine (M) ; or (ii) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 1 lacking the N-terminal methionine (M) .
[0122] In some embodiment, RNA-guided DNA binding agent retains the RNA-guided DNA binding activity. In some embodiments, the RNA-guided DNA binding agent recognizes a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) . In some embodiments, the RNA-guided DNA binding agent comprises an amino acid substitution at a position corresponding to residue 11, and / or 587 of SEQ ID NO: 1. In some embodiments, said one or more mutations selected from the group consisting of D11A and H587A, wherein each mutation is at a position corresponding to that of SEQ ID NO: 1.
[0123] In some embodiments, the RNA-guided DNA binding agent comprises an amino acid sequence selected from: (i) a sequence of any one of SEQ ID NOs: 201-203; or (ii) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to any one of SEQ ID NOs: 201-203. In some embodiments, the RNA-guided DNA binding agent comprises an amino acid sequence selected from: (i) a sequence of SEQ ID NOs: 201-203, lacking the N-terminal methionine (M) ; or (ii) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NOs: 201-203, lacking the N-terminal methionine (M) .
[0124] In certain embodiments, the reference sequence used for sequence identity comparison includes the N-terminal initiating methionine (M) at position 1. It will be understood by those of skill in the art that an engineered RNA-guided DNA binding agent may lack this N-terminal methionine (e.g., due to processing, deletion, or replacement) . For such a variant, if the remaining amino acid sequence (i.e., the sequence other than the missing N-terminal methionine) shares at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%sequence identity with the corresponding region of the reference sequence (i.e., the region spanning from position 2 to the C-terminus) , such variant is still encompassed by the present disclosure.
[0125] In some embodiments, an effector domain is fused with the RNA-guided DNA-binding agent, forming a chimeric polypeptide, and encapsulated in the VLP. In some embodiments, the effector domain comprises sequences selected from the group consisting of: a nuclear localization signal sequence, a nuclear export signal sequence, a cell-penetrating peptide sequence, an affinity tag sequence, a deaminase sequence, a reverse transcriptase sequence, a recombinase sequence, a methyltransferase sequence, a methylase sequence, an acetylase sequence, an acetyltransferase sequence, a transcriptional activator sequence, a transcriptional repressor domain sequence, a cryptochrome sequence, a light inducible / controllable domain sequence, a chemically inducible / controllable domain sequence, and a replication initiation protein sequence. In some embodiments, the chimeric polypeptide further comprises one or more NLSs. In some embodiments, the chimeric polypeptide comprises 1-7 NLSs. In some embodiments, the chimeric polypeptide comprises 3-6 NLSs. In some embodiments, the chimeric polypeptide comprises 1, 2, 3, 4, 5, 6, or 7 NLS (s) . In some embodiments, the chimeric polypeptide comprises at least one NLS at N-terminus. In some embodiments, the chimeric polypeptide comprises at least one NLS at C-terminus. In some embodiments, the chimeric polypeptide comprises at least one NLS at N-terminus and at least one NLS at C-terminus. In some exemplary embodiments, the at least one of the NLS has a sequence of any one of SEQ ID NOs: 25, 26, 233, and 234.
[0126] In some embodiments, the chimeric polypeptide comprises an amino acid sequence selected from: (i) a sequence of SEQ ID NO: 222 or SEQ ID NO: 24 ; or (ii) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to SEQ ID NO: 222 or SEQ ID NO: 24.
[0127] In some embodiments, the Gag polypeptide and the RNA-guided DNA binding agent are initially present in the form of a fusion protein wherein they are connected by a cleavable linker, and the cleavable linker has been cleaved, at least in part, by a protease of a Gag-pol polyprotein contained within / assembled into the VLP such that, at least a portion, the RNA-guided DNA binding agent is released as a separate polypeptide inside the VLP. In some embodiments, the cleavage may be complete, such that the RNA-guided DNA binding agent is fully released as a separate polypeptide, or incomplete, such that the VLP comprises both the released separate polypeptide and the uncleaved fusion protein. In some other embodiments, In some embodiments, the VLP does not comprise a cleavable linker between the Gag polypeptide and the RNA-guided DNA binding agent, and the Gag polypeptide and the RNA-guided DNA binding agent are present in the VLP as a fusion protein, wherein the Gag polypeptide is optionally engineered, for example truncated, to permit the function of the RNA-guided DNA binding agent within the fusion protein. In some exemplary embodiments, at least one cleavable linker has a sequence of SEQ ID NO: 232.
[0128] In some embodiments, the fusion protein further comprises one or more NESs. In some embodiments, the fusion protein comprises 1-7 NESs. In some embodiments, the fusion comprises 3-6 NESs. In some embodiments, the fusion comprises 1, 2, 3, 4, 5, 6, or 7 NES (s) . In some embodiments, one or more NESs is positioned between the Gag domain and the protease-cleavable linker. In some embodiments, at least one NES is inserted between the subdomains of the Gag domain. In some exemplary embodiments, at least one of the NES has a sequence of SEQ ID NO: 231 (Table 2) .
[0129] The present disclosure also provides a gRNA, or a polynucleotide encoding the gRNA. The present disclosure further provides a polynucleotide encoding the RNA-guided DNA binding agent of the present disclosure. The CRISPR-Cas system of the present disclosure may comprise (i) such gRNA or a polynucleotide encoding the gRNA, and (ii) the RNA-guided DNA binding agent of the present disclosure or a polynucleotide encoding the same. In some exemplary embodiments, the VLPs of the present disclosure also comprise the gRNA of the present disclosure, or a polynucleotide encoding the gRNA.
[0130] In some embodiments, the gRNA comprises a spacer sequence that is complementary to a target sequence; and a binding segment that interacts with the RNA-guided DNA binding agent, wherein the RNA-guided DNA binding agent binding segment comprises a tracrRNA sequence and a direct repeat (DR) sequence, and wherein the tracrRNA sequence hybridizes with the DR sequence to form a double-stranded RNA (dsRNA) duplex. Some exemplary DR sequences and tracrRNA sequences are listed in Table 3 and Table 4. In some embodiment, the target sequence is located adjacent to a protospacer adjacent motif (PAM) comprising the sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .
[0131] In some embodiments, the gRNA is a dual guide RNA. In some embodiments, the gRNA is a single guide RNA (sgRNA) .
[0132] In some embodiments, the tracrRNA sequence is selected from: (a) any one of SEQ ID NO: 3 and SEQ ID NO: 4; and (b) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to any one of SEQ ID NO: 3 and SEQ ID NO: 4.
[0133] In some embodiments, the DR sequence is selected from: (a) any one of SEQ ID NO: 5 and SEQ ID NO: 6; and (b) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to any one of SEQ ID NO: 5 and SEQ ID NO: 6.
[0134] In some embodiments, the gRNA comprises, in the 5'to 3'direction, a spacer sequence, a direct repeat (DR) sequence, and a tracrRNA sequence, wherein the DR sequence and the tracrRNA sequence are capable of hybridizing to form a double-stranded structure. In some embodiments, the gRNA is configured such that the spacer, the DR, and the tracrRNA are arranged contiguously in a 5’ to 3’ order. In some embodiments, the gRNA further comprises a linker sequence connecting the tracrRNA sequence and the DR sequence to form a sgRNA scaffold. In some embodiments, a linker of 3 to 10 nucleotides (e.g., GAAA) is interposed between the DR and the tracrRNA to form a single transcript. Thus, the linear arrangement can be represented as: 5’ - [spacer] - [DR] - [linker] - [tracrRNA] -3’ . In some embodiments, when the gRNA is expressed as two separate molecules, a crRNA comprising the spacer and the DR (5’ - [spacer] - [DR] -3’ ) forms a complex with a tracrRNA through base-pairing between the DR and a complementary region at the 5’ end of the tracrRNA. In some typical embodiments, the linker comprises a short sequence of GAAA. In some embodiments, the linker serves as an artificial loop. In some exemplary embodiments, a typical structure of the sgRNA can be represented as NNNNNNNNNNNNNNNNNNNN-scaffold, wherein the consecutive “N” sdenote the spacer portion and are presented merely by way of example, without implying any limitation on the specific number of nucleotides in the spacer. The spacer may be longer than 20 nucleotides (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) , shorter than 20 nucleotides (e.g., 15, 16, 17, 18, or 19) , or exactly 20 nucleotides. Some exemplary scaffold sequences are listed in Table 5.
[0135] In some embodiments, the scaffold sequence is selected from: (a) any one of SEQ ID NO: 7 and SEQ ID NO: 8; and (b) a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity to any one of SEQ ID NO: 7 and SEQ ID NO: 8.
[0136] In some embodiments, the spacer sequence has a length of 15 to 30 nucleotides. For example, the spacer sequence may be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.
[0137] In some embodiments, the spacer sequence of the gRNA (a) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (b) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148 (e.g., at least 16, 17, 18, 19, 20, 21, 22, 23, or 24 contiguous nucleotides thereof) ; or (c) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148 (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%sequence identity thereto) .
[0138] In some embodiments, at least three nucleotides of the gRNA are modified. The modifications may include, but are not limited to, modifications at the 3’ end of the spacer region (e.g., the last 3, 4, 5, or 6 nucleotides) , one or more nucleotides within the hairpin structures, and / or one or more nucleotides within the loop structures. Such modifications may comprise 2’ -O-methyl, 2’ -fluoro, phosphorothioate, and / or backbone modifications, provided that the modifications do not substantially impair the binding of the gRNA to the RNA-guided DNA binding agent or the formation of the R-loop.
[0139] In some embodiments, a donor template nucleic acid may be included in the VLP or the CRISPR-Cas system as described in this disclosure. In some embodiments, the donor template nucleic acid is a double-stranded nucleic acid. In some embodiments, the donor template nucleic acid is a single-stranded nucleic acid. In yet other embodiments, the donor template nucleic acid comprises both single-stranded and double-stranded portion. In some embodiments, the donor template nucleic acid is linear. In some embodiments, the donor template nucleic acid is circular. In some embodiments, the donor template nucleic acid is an exogenous nucleic acid molecule. In some embodiments, the donor template nucleic acid is an endogenous nucleic acid molecule. In some embodiments, the donor template nucleic acid is capable of being inserted into a target site. Once inserted, the donor template nucleic acid may express a corresponding product (e.g., a CAR or a therapeutic protein) either independently, or jointly with the target site sequence, for instance, as a fusion protein.
[0140] This disclosure also provides a method of modifying a target DNA sequence in a cell, comprising contacting the cell with the RNA-guided DNA binding agent, the CRISPR-Cas system or the VLP of this disclosure, wherein the target DNA sequence is adjacent to a PAM comprising the sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .
[0141] Table 1: The amino acid sequences of the RNA-guided DNA binding agent
[0142] Table 2: The exemplary NLS, NES and Protease cleavable linker
[0143] Table 3: The tracrRNA sequence of the Cas proteins:
[0144] Table 4: The nucleotide sequence of the DR described in the disclosure
[0145] Table 5: The sequence encoding the sgRNA scaffold of the Cas proteins: Other Definitions
[0146] It should be noted that as used herein and in the appended claims, the singular forms or the terms “a” , “an” , “the” and similar terms used in the context of the present disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In some embodiments, the above terms can be reasonably comprehended as “one” or “one or more” . Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0147] Unless otherwise indicated, all singular and plural terms used herein are intended to encompass their respective singular and plural forms. Additionally, terms used in the present tense are intended to encompass their past and future tense forms, and vice versa, as appropriate depending on the context of the description. This interpretation applies to all terms used in the specification, claims, and drawings, unless explicitly stated otherwise. For example, the term “cell” may refer to a single cell or multiple cells, and the term “delivers” may refer to the action of delivering in the past, present, or future, as understood from the context.
[0148] It is noted that in this disclosure and particularly in the claims and / or paragraphs, terms such as “comprises” , “comprised” , “comprising” and the like can have the meaning attributed to it in U. S. Patent law; e.g., they can mean “includes” , “included” , “including” , and the like; and those terms such as “consisting essentially of” and “consists essentially of” have the meaning ascribed to them in U.S. Patent law.
[0149] The term “identity” in the context of two or more nucleic acids or polypeptide sequences refers to two or more sequences or subsequences that are the same or have specified percentage of amino acid residues or nucleotides that are the same as measured using a BLAST or BLAST 2.0 or FASTA etc. sequence comparison algorithms with default parameters described below.
[0150] The term “exemplary” is used herein to mean serving as an example, instance or illustration. Any aspect or design described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects, embodiments, or designs.
[0151] As used herein, the term “optional” or “optionally” means that the subsequent described event, circumstance or substituent may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0152] Various embodiments are described herein. It should be noted that these specific embodiments are not intended to be exhaustive or to limit the broader aspects discussed in this disclosure. Any aspect described in connection with a particular embodiment is not necessarily limited to that embodiment and may be applied to other embodiments. Throughout this specification, references to 'in some embodiments, ' 'in certain embodiments, ' 'in some specific embodiments, ' 'in specific embodiments, ' 'in some cases, ' or similar expressions mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Additionally, particular features, structures, or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art, in one or more embodiments. Furthermore, while some embodiments described herein may include certain features but not others, combinations of features from different embodiments are intended to fall within the scope of this disclosure. For example, in the appended claims, any of the claimed embodiments may be used in any combination. The embodiments described herein are provided to enable a person skilled in the art to make and use the invention, and are not intended to limit the scope of the disclosure. Any combination of features described in the specification, whether explicitly stated or implied, is within the scope of the present disclosure.
[0153] When “t” or “T” appears in a sequence in this disclosure as a nucleotide of an RNA sequence, it should be understood as “u” or “U” .
[0154] As used in this disclosure, the term “located therebetween” or “located between” in reference to the cleavable linker refers to the linker being located within a linear or non-linear arrangement connecting two components (e.g., Gag polypeptide and DNA binding agent) , regardless of whether additional functional domains (e.g., nuclear export signals, localization sequences, or epitope tags) are present between the two components. The linker may be directly adjacent to either or both components, or separated by intervening domains
[0155] As presented in this disclosure, the terms “structural protein (s) ” , “structural component (s) ” , or their derivatives, in any tense-past, present, or future-and in either singular or plural form, refer to proteins that contribute to the overall structure of a VLP as disclosed herein or a viral. The presence of structural proteins facilitates the self-assembly of VLP. The term “structural protein” further includes functional variant, fragments or derivatives of such protein contributing to the structure of a capsid protein or of protein core of a VLP or a viral. Typically, the structural proteins are localized inside the core of the VLP or a viral.
[0156] As presented in this disclosure, the term “derived from, ” “derived” or other similar expressions, in reference to a protein originating from a specified species (e.g., virus or other species) , encompasses proteins that either (1) directly originate from such species or are recombinantly produced with ≥80%sequence identity to the native protein, and / or (2) retain part of or all core functional characteristics of the native protein, including engineered variants (e.g., mutations) that preserve these functions.
[0157] In this disclosure, the editing efficiency (e.g., the “editing percentage” or “percent editing” or “indel frequency” ) is defined as the total number of sequences reads with insertions / deletions ( “indels” ) or substitutions over the total number of sequences reads, including wild type.
[0158] As presented in this disclosure, the use of “or” or “ / ” is inclusive and means “and / or” unless stated otherwise; or it could be interpreted differently based on the context. The term “and / or” as used herein a phrase such as “A and / or B” is intended to include both A and B; A or B; A (alone) ; and B (alone) . Likewise, the term “and / or” as used herein a phrase such as “A, B, and / or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone) ; B (alone) ; and C (alone) .
[0159] The following non-limiting examples are provided to further illustrate embodiments of the disclosure disclosed herein. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent approaches that have been found to function well in the practice of the disclosure, and thus can be considered to constitute examples of modes for its practice. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure. EXAMPLES
[0160] For each example, it is noted that, the sgRNA is defined by the general architecture 5’ - [spacer] - [scaffold] -3’ (e.g., NNNNNNNNNNNNNNNNNNNN-scaffold) unless otherwise stated. The consecutive “N” sdenote the spacer portion and are presented merely by way of example, without implying any limitation on the specific number of nucleotides in the spacer. The spacer may be longer than 20 nucleotides (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) , shorter than 20 nucleotides (e.g., 15, 16, 17, 18, or 19) , or exactly 20 nucleotides. The person skilled in the art knows that the spacer and scaffold can be combined in said 5’ -to-3’ orientation to form the intact sgRNA without any structural ambiguity.
[0161] EXAMPLE 1: Metagenomic mining and structure modeling of GEBx0321
[0162] A homology-based search was conducted using Hidden Markov Models (HMMs) constructed from a curated database of Class 2 Type II CRISPR-Cas effector proteins and related Cas homologs. The HMM profiles were iteratively trained on conserved domains (e.g., RuvC-like endonuclease, HNH motifs) derived from reference sequences. Candidate CRISPR-Cas proteins identified through this search were subjected to multiple sequence alignment (MSA) against structurally characterized Cas9 orthologs using MAFFT (v7.520) .
[0163] The metagenomic workflow culminated in the identification of a novel Type II CRISPR-Cas effector protein GEBx0321 exhibiting a divergent REC lobe topology and catalytically essential residues (D11 / H587) . Structural validation by AlphaFold3 corroborated conserved RuvC domain architecture, while surface electrostatics analysis revealed unique DNA-binding groove adaptations potentially enabling protospacer-adjacent motif (PAM) plasticity (FIG. 1) .
[0164] The domain arrangement was annotated and shown in FIG. 2. The GEBx0321 protein contains a RuvC domain, BH (bridge helix) domain, REC domain, HNH domain and CTD (C-terminal domain) , wherein RuvC domain contains three split RuvC sub-domains.
[0165] EXAMPLE 2: PAM determination in mammalian cell line
[0166] In a set of experiments, the HEK293T cells were cultured in DMEM medium supplemented with 10%fetal bovine serum (GibcoTM) . For transfection, cells were seeded in a 24-well plate at 120, 000 cells / well in 450 μL medium 24 hours prior. Transfection was performed using LipofectamineTM 3000 (Invitrogen, Cat. L3000015) according to the manufacturer’s protocol. Each well received 50 μL of lipoplex containing: GEBx0321 plasmid (harboring GEBx0321 CDS, SEQ ID NO: 28, 400 ng) , gRNA plasmid (harboring sgRNA encoding sequence with Humanspacer3 spacer and GEBx0321-PT-V1 / GEBx0321-PT-V2 scaffold sequence, 150 ng) , dsODN (annealed from oligonucleotides SEQ ID NO: 10 and SEQ ID NO: 11, 2.5 pM / well) , LipofectamineTM 3000 (1.5 μL / well) , P3000 (1.5 μL / well) and OptiMemTM to adjust volume. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours.
[0167] Following transfection, cellular supernatants were aspirated and adherent cells underwent three PBS (pH 7.4) washes to remove residual serum proteins. Genomic DNA was subsequently extracted from 24-well plate cultures using the Genomic DNA Extraction Kit (Denogen, Beijing, DNS033-48) following the manufacturer's protocol. DNA integrity was verified via 0.8%agarose gel electrophoresis, with quantification performed using NanoDrop OneC spectrophotometry (Thermo Scientific) demonstrating optimal purity (260 / 280 = 1.8–2.0) and concentration (~200 ng / μL) .
[0168] Guide-Seq library preparation was performed as previously described (Nikolay et al., Nat. Protoc. 2021) with modifications. Briefly, genomic DNA (500 ng per sample) was fragmented using the KAPA Frag Kit (Cat#KK8602; Roche) and purified using SPRI Select beads (Cat#B23318; Beckman Coulter) . Fragments were subsequently phosphorylated with T4 Polynucleotide Kinase (Cat#M0201S; New England Biolabs, NEB) , followed by ligation of a pre-annealed SS5 adapter (SS5TOP: SS5BTM oligos, 10 μM each) using the Quick LigationTM Kit (Cat#M2200S; NEB) .
[0169] Two-step nested PCR amplification was then performed to enrich off-target sequences: Primary PCR: Reactions contained PlatinumTM Taq DNA Polymerase (Cat#15966005; Invitrogen) , GSP1 primers (GSP1-Top / GSP1-BoT mix) , and Y_XX indexing primers; Secondary PCR: Reactions utilized GSP2 primers (GSP2-TopA / B / C and GSP1-BoTA / B / C mix) , Y_XX primers (identical to primary PCR) , and i753_XX primers.
[0170] All intermediate DNA products were purified with SPRI Select beads. Final libraries were quantified via qPCR and sequenced on an Illumina NextSeq 1000 platform (2×150 bp paired-end) . Raw reads (Q30 score > 90%; read length: 130–140 bp) were aligned to the human reference genome (hg38) using BWA-MEM. BAM files were filtered to retain high-quality mapped reads, followed by targeted extraction of sequences overlapping predefined genomic regions of interest. The nucleotide sequences used in this example are listed in Table 6.
[0171] Table 6: The nucleotide sequences used in this example
[0172] Note: p: phosphorylation modification; *: phosphorothioate (PS) bond; “N” may be any natural or non-natural nucleotide.
[0173] The amino acid sequence of RNA-guided DNA binding protein with nuclear localization signals (NLSs) and FLAG-tagged sequence is shown in SEQ ID NO: 24, Table 7. The exemplary nucleotide sequences encoding the RNA-guided DNA binding protein with or without NLS and FLAG-tag are shown in Table 8.
[0174] Table 7: The amino acid sequence of the RNA-guided DNA binding protein sequences with NLSs and Flag-tag, the NLS sequences and FLAG-tagged sequence.
[0175] Table 8: The nucleotide sequence encoding the RNA-guided DNA binding protein with or without NLS and FLAG-tag
[0176] The PAM sequence preference of wild-type GEBx00321 in HEK293T cells was systematically characterized (FIG. 3) . Comprehensive analysis revealed that GEBx0321 exhibits strong binding specificity for a non-canonical PAM motif with the sequence NNNNCAAA, where the degenerate nucleotide positions (N = A / T / G / C) precede a conserved core motif (CAAA) .
[0177] EXAMPLE 3: In vitro gene editing in mammalian cell lines
[0178] In a set of experiments, the HEK293T cells were cultured in DMEM medium supplemented with 10%fetal bovine serum (GibcoTM) . For transfection, cells were seeded in a 96-well plate at 25, 000 cells / well in 100 μL medium 24 hours prior. Transfection was performed using LipofectamineTM 3000 (Invitrogen, Cat. L3000015) according to the manufacturer’s protocol. Each well received 25 μL of lipoplex containing: Cas9 plasmid (harboring Cas9 CDS, 150 ng) , gRNA plasmid (encoding sgRNA, 75 ng) , LipofectamineTM 3000 (0.6 μL / well) , P3000 (0.6 μL / well) and OptiMemTM to adjust volume. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours.
[0179] Following transfection, cellular supernatants were aspirated and adherent cells underwent three PBS (pH 7.4) washes to remove residual serum proteins. Genomic DNA was subsequently extracted from 24-well plate cultures using the Genomic DNA Extraction Kit (Denogen, Beijing, DNS033-48) following the manufacturer's protocol. DNA integrity was verified via 0.8%agarose gel electrophoresis, with quantification performed using NanoDrop OneC spectrophotometry (Thermo Scientific) demonstrating optimal purity (260 / 280 = 1.8–2.0) and concentration (~50 ng / μL) .
[0180] Amplicon-Seq NGS analysis was performed to assess CRISPR-Cas9 editing efficiency. Custom primers flanking the target genes were designed for amplicon generation. Library preparation was subsequently performed through adapter ligation PCR following the manufacturer's recommended protocol (Illumina, San Diego, CA) . High-throughput sequencing was conducted on an Illumina iSeq 100 platform, generating paired-end reads (130-140 bp) with a Q30 quality score exceeding 90%.
[0181] Raw sequencing data underwent stringent quality control processing, including: trimming of low-quality bases (Phred score <30) using Fastp v0.23.2; alignment to the amplicon-specific reference sequences via CRISPResso2 v2.2.12; removal of artifactual duplicates using CRISPResso2's integrated UMI-aware deduplication module. Mapped reads demonstrating complete overlap with designated target loci were subjected to variant analysis. A minimum coverage depth of 1, 000×was maintained across all targets. Variant calling was performed through comparative analysis of aligned reads against the reference sequence to quantify wild-type versus mutant alleles containing indels or single nucleotide variants (SNVs) . Statistical significance was determined using Fisher's exact test with Bonferroni correction (p<0.01) .
[0182] An in vitro experiment was conducted in HEK293T cell line to evaluate the activity of GEBx0321 at 19 target sites across three disease-relevant loci: CFTR, POLQ and RNF2. Cas9 plasmid harboring GEBx0321 CDS (SEQ ID NO: 28) was co-transfected with the Guide-RNA plasmid encoding sgRNA (harboring GEBx321-PT-V2 sgRNA scaffold, SEQ ID NO: 8 and different spacers, SEQ ID NOs: 29-52, Table 9) . Deep sequencing analysis demonstrated variable editing efficiencies ranging from 9.40%to 37.80% (FIG. 4) . Notably, the CFTR-NNNNCAAA-sg7 locus exhibited peak activity (37.80 ± 0.90%, mean ± SD, n=3) , whereas CFTR-NNNNCAAA-sg2 targets showed reduced efficiency (9.40 ± 1.01%, mean ±SD, n=3) , potentially reflecting chromatin accessibility differences.
[0183] Table 9: CRISPR target loci and sgRNA spacer sequences for CFTR, POLQ, and RNF2 in Example 3
[0184] The spacer sequence is located at the 5’ end of the scaffold. And the 3'end of each spacer sequence is directly linked to the 5’ end of the subsequent scaffold sequence, forming the characteristic repeat-spacer pattern.
[0185] EXAMPLE 4: Engineered virus-like particles (VLPs) -mediated in vitro gene editing in mammalian cell lines
[0186] This example was conducted to verify whether the GEBx0321 is compatible with the VLP delivery platform.
[0187] VLP production: The VLP packaging procedure was initiated by seeding HEK293T cells at a density of 1.13 × 106 cells per T25 flask in 6.5 mL DMEM supplemented with 10%FBS 48 hours prior to transfection, allowing cells to reach 80-90%confluency under standard culture conditions (37℃, 5%CO2) . Transfection complexes were prepared by combining plasmids containing sequences encoding envelope protein (SEQ ID NO: 139) , Gag-pol (SEQ ID NO: 136) , and Gag-GEBx0321 (SEQ ID NO: 133) and sgRNA. All the VLP packaging plasmids were dissolved in 166 μL Opti-MEM, followed by mixing with PEI (Polysciences 24765-1) dissolved in 166 μL Opti-MEM at a 3: 1 (w / w) polymer: DNA ratio through dropwise addition and 10-second vertexing. After 10-minute incubation at room temperature for nanoparticle formation, the DNA-PEI complexes were administered to cells cultured in 3 mL fresh DMEM / 10%FBS medium, with a 6-hour incubation prior to medium replacement with 6.5 mL serum-free DMEM. Supernatants were harvested 48 hours post-transfection through 0.45 μm PVDF filtration, precipitated overnight at 4℃ with 1.7 mL 50% (w / w) PEG8000 (Sigma 89510) under gentle agitation (50 rpm) , and concentrated via centrifugation at 50, 000 g for 2 hours (4 ℃) . The resultant VLP pellets were resuspended in 120 μL sterile PBS (pH 7.4) to generate 50× concentrated stocks or 60 μL PBS to generate 100×concentrated stocks, which were aliquoted and stored at -80℃ with ≤3 freeze-thaw cycles permitted.
[0188] For transfection, cells were seeded in a 96-well plate at 20, 000 cells / well in 100 μL medium 24 hours prior. Each well received 2 μL (Dose 1, D1) or 10 μL (Dose 2, D1) of VLP 50× concentrated stocks. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. DNA extraction, amplicon sequencing, and data analysis were performed as described in Example 3.
[0189] An in vitro experiment was performed in the HEK293T cell line to assess the gene editing activity mediated by GEBx0321-loaded VLPs at 12 target sites spanning three disease-associated loci: CFTR, POLQ, and RNF2. VLPs packaged as described above, carrying GEBx0321 protein and sgRNA (harboring GEBx321-PT-V2 sgRNA scaffold, SEQ ID NO: 8 and different spacers, SEQ ID NOs: 29-52) , were transfected into the cells. Deep sequencing analysis (results were shown in FIG. 5) demonstrated variable editing efficiencies and revealed a strong dose dependent effect: D2 consistently enhances efficiency compared to D1, particularly for low-performing sgRNAs (e.g., POLQ-NNNNCAAA-sg4 efficiency increased from 1.55 in D1 to 11.55 in D2) . Gene and sgRNA specific variations were prominent, with CFT2-NNNNCAAA-sg7, POLQ-NNNNCAAA-sg2 and RFN2-NNNNCAAA-sg7 achieving near-saturation efficiency in D2 (>95%) , while others like POLQ-NNNNCAAA-sg5 remained suboptimal (<2%) . These results highlight the critical interplay between sgRNA design, target gene, and drug dose in optimizing editing outcomes, suggesting prioritized validation of high efficiency guides and dose refinement for translational applications.
[0190] Based on the aforementioned findings, we assessed the editing activity of another RNA-guided DNA binding agent GEBx0305 using lipoplex and VLP delivery systems at the same target gene and compared with GEBx0321. VLP production, Cell transfection, DNA extraction, amplicon sequencing, and data analysis were performed as described in Example 3 and Example 4. The sequences of GEBx0305 (SEQ ID NO: 87) , the corresponding gRNA and spacer sequences are listed in Table 10. Although GEBx0305 also exhibits high activity upon lipoplex-mediated delivery, its activity becomes very poor when packaged with VLP. In contrast, GEBx0321 is highly compatible with the VLP delivery platform and is not affected by the VLP formation process or any components present in the VLP (FIG. 6) .
[0191] Table 10: sgRNA, scaffold and spacer sequences for CFTR, POLQ, and RNF2 in this Example.
[0192] Note: The “N” denotes any natural or non-natural nucleotide. The notation (N) n denotes a contiguous sequence of n nucleotides, where n is a positive integer and corresponds to the length of the spacer region. The specific value of n shown in any illustration is exemplary only and does not limit the actual length. Depending on the specific design requirements of the RNA, n may be any integer from 15 to 26 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26) .
[0193] EXAMPLE 5: Genome-wide off-target profiling of GEBx0321 delivered via lipoplexes and VLPs
[0194] To evaluate the off-target effects of GEBx0321 when delivered by VLP, another experiment was performed.
[0195] In a set of experiments, the HEK293T cells were cultured in DMEM medium supplemented with 10%FBS.
[0196] For lipoplexes transfection, cells were seeded in a 24-well plate at 120, 000 cells / well in 450 μL medium 24 hours prior. Transfection was performed using LipofectamineTM 3000 according to the manufacturer’s protocol. Each well received 50 μL of lipoplex containing: Cas9 plasmid (harboring GEBx0321 CDS, SEQ ID NO: 28, 400 ng) , gRNA plasmid (encoding GEBx321-Pt-V1-CFTR-NNNNCAAA-sg7, GEBx321-Pt-V1-POLQ-NNNNCAAA-sg2 or GEBx321-Pt-V2-RNF2-NNNNCAAA-sg7 sgRNA, 150 ng) , dsODN (annealed from oligonucleotides SEQ ID NO: 10 and 11, 2.5 pM / well) , LipofectamineTM 3000 (1.5 μL / well) , P3000 (1.5 μL / well) and OptiMemTM to adjust volume. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours.
[0197] For VLPs transfection, cells were seeded in a 24-well plate at 120, 000 cells / well in 450 μL medium 24 hours prior. Each well was initially treated with 50 μL of lipoplex containing: dsODN (annealed from oligonucleotides SEQ ID NO: 10 and 11 at 2.5 pM / well) , LipofectamineTM 3000 (1.5 μL) , P3000 (1.5 μL) , and Opti-MEMTM medium to adjust volume. After a 4-hour incubation, 10 μL of 50×concentrated VLPs (carrying GEBx0321 protein and GEBx0321-Pt-V1-CFTR-NNNNCAAA-sg7, GEBx0321-Pt-V1-POLQ-NNNNCAAA-sg2 or GEBx0321-Pt-V2-RNF2-NNNNCAAA-sg7 sgRNA) was added to each well. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours.
[0198] DNA extraction and Guide-Seq-based NGS analysis were performed as described in Example 2. Deep sequencing analysis revealed minimal off-target activity in the HEK293T cell lines at CFTR-NNNNCAAA-sg7, POLQ-NNNNCAAA-sg2 and RNF2-NNNNCAAA-sg7 targets for both plasmid-and VLP-mediated delivery systems (FIG. 7) . The results show that when GEBx0321 is delivered by VLP, it achieves very low off-target effects while maintaining high editing activity, demonstrating the safety of this system and expanding its application potential.
[0199] EXAMPLE 6 and EXAMPLE 7 were conducted to further assess its application potential.
[0200] EXAMPLE 6: Screening optimal spacer sequences and transfection doses for GEBx0321-Mediated CRISPR Editing of the Mouse Transthyretin (mTTR) Gene
[0201] The VLP packaging procedure was performed as described in Example 4, except that the SgRNA was selected from the sequences in Table 11. In a set of experiments, the Hepa 1-6 cell were cultured in DMEM medium supplemented with 10%fetal bovine serum (GibcoTM) . For transfection, cells were seeded in a 96-well plate at 20, 000 cells / well in 100 μL medium 24 hours prior. Each well received 2 μL (low dosage) or 10 μL (High dosage) of VLP 50× concentrated stocks. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. DNA extraction amplicon sequencing, and data analysis were performed as described in Example 3.
[0202] Table 11: The exemplary spacer sequences and sgRNA sequences related specific knock out at mTTR locus
[0203] An in vitro experiment was performed in the Hepa 1-6 cell line to assess the gene editing activity mediated by GEBx0321 RNP-loaded VLPs at 7 target sites spanning mTTR locus. VLPs packaged as described above, carrying GEBx0321 protein and sgRNA targeting mTTR locus (SEQ ID NOs: 60-66, Table 11) , were transfected into the cells. Deep sequencing analysis demonstrated peak editing efficiency of 53.00% (low dose) and 91.73% (high dose) at the mTTR-NNNNCAAA-sg6 site. (FIG. 8)
[0204] To evaluate dose-dependent editing efficiency, a second in vitro assay in Hepa1-6 cells quantified CRISPR activity of GEBx0321-loaded VLPs at mTTR-NNNNCAAA-sg6 target site. VLPs were tested at three concentration levels: 1× stocks (1 μL, 2 μL, 5 μL, 10 μL, 20 μL) , 10× stocks (1 μL, 2 μL, 5 μL) and 100×stocks (1 μL, 2 μL, 5 μL) . Deep sequencing analysis revealed near-saturated editing levels at low dosage treatment with a 100× stock solution. (FIG. 9)
[0205] EXAMPLE 7: in vivo VLP-mediated editing of the mTTR locus.
[0206] For in vivo study, A total of 12 CD1 strain mice (age 6-8 Week) were divided into two groups. Each group received a specific dose of VLP (carrying GEBx0321 protein and GEBx0321-PT-V2-mTTR-NNNNCAAA-sg6 sgRNA, SEQ ID NO: 65, with dosage volumes of 100 μL for low dosage group and 200 μL for high dosage group) via intravenous administration on day 0. Following treatment, mice were euthanized at day 3 for comprehensive tissue collection, including whole blood, liver, spleen, kidneys (unilateral) , lungs (all five lobes) , heart, and gonads (testes for males or ovaries for females) . Tissue gDNA was extracted with the Genomic DNA Extraction Kit (Denogen, Beijing, DNS033-48) following the manufacturer’s protocol. Amplicon-Seq-based NGS analysis were performed as described in Example 3. Serum samples obtained through centrifugation were subjected to hepatic transaminase analysis using IFCC-recommended enzymatic assays on an automated biochemistry analyzer.
[0207] Deep sequencing analysis demonstrated that the GEBx0321 RNP-loaded VLP achieved peak editing efficiency in mice’s liver (64.28%, high dosage group) and modest activity in spleen (8.27%, high dosage group) . Only minimal editing signals (below 1%threshold) were observed in kidneys, lungs, heart, and gonads tissues, indicating negligible off-target activity (FIG. 10) . Hepatic transaminase analysis revealed no significant hepatotoxicity (ALT / AST levels within physiological ranges) across all tested dose regimens (FIG. 11) . These results demonstrate that the GEBx0321 RNP-loaded VLP exhibits high editing efficiency in the liver with minimal off-target effects in other tissues and no detectable hepatotoxicity, highlighting its great potential for in vivo therapeutic applications.
[0208] EXAMPLE 8: Engineered virus-like particles (VLPs) -mediated in vitro gene editing in HCE-T cells
[0209] To further evaluate the application potential of VLP-delivered GEBx0321, another gene editing experiment was performed in a different cell type for validation.
[0210] VLP production was performed using the same method as described in Example 4. For transfection, HCE-T cells were seeded in a 96-well plate at 20,000 cells / well in 100 μL HCE-T Cell complete medium (Pricella, Cat. CM-0743) 24 hours prior. Each well received 2 μL or 10 μL of VLP 50× concentrated stocks. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. DNA extraction amplicon sequencing, and data analysis were performed as described in Example 3.
[0211] An in vitro experiment was performed in HCE-T cells to assess the gene editing activity mediated by GEBx0321-loaded VLPs at 14 distinct target sites within the human TGFBI (hTGFBI) locus. VLPs packaged as described above, carrying GEBx0321 protein and sgRNA (harboring GEBx0321-PT-V2 sgRNA scaffold, SEQ ID NO: 8 and hTGFBI-T1~T14 spacer, SEQ ID NOs: 91-104, Table 12) , were transfected into the cells. Deep sequencing analysis demonstrated that GEBx0321 delivered via VLPs achieved editing efficiencies of >90%at hTGFBI-T3 / 5 / 6 / 10 target sites. The spacer sequences of hTGFBI-T1 to T14 are listed in Table 12, and the results are presented in FIG. 12.
[0212] Table 12: sgRNA spacer sequences of hTGFBI-T1~T14 in this example.
[0213] EXAMPLE 9: Engineered virus-like particles (VLPs) -mediated in vitro gene editing efficiency in human CD3+ T cells
[0214] We further evaluated the activity of VLP-delivered GEBx0321 in human CD3+ T cells.
[0215] VLP production was performed using a method similar to that in Example 4. Generally, LentiX cells were seeded into packaging consisting of DMEM supplemented with 10%FBS. Cells were transfected the next day (or the day after the next, depending on seeding density) with the plasmids comprise sequences encoding an envelope protein (SEQ ID NO: 134) , a T cell-targeted binder (SEQ ID NO: 135, Table 14) , Gag-GEBx0321 fusion protein (SEQ ID NO: 132 or SEQ ID NO: 133, Table 14) , Gag-pol (SEQ ID NO: 131 or SEQ ID NO: 136, Table 14) , and a sgRNA (SEQ ID NOs: 114-116, Table 13) . Six hours after transfection, medium was replaced with DMEM without FBS. Two days after transfection, supernatant was collected and VLP particles were precipitated with PEG overnight and concentrated to 50x in PBS.
[0216] Table 13: The sequences or sequences encoding the VLP components.
[0217] Table 14: The amino acid sequences of the exemplary components of the VLP
[0218] To test editing efficiency, resting human CD3+ T cells were thawed and recovered in T cell medium overnight. The next day, T cells were seeded at 2e4 per well in 96-well plate. 10ul or 20ul 50xVLP were added to each well by triplicate. Six days later, T cells were collected for lysis and NGS sequencing. Editing efficiency at the targeted sites were quantified by CRISPRESSO2. The editing efficiency was shown FIG. 13. The results show that VLP-delivered GEBx0321 also exhibited high activity in resting human CD3+ T cells. Meanwhile, adjustment of VLP components (CA0 and CA3) did not affect the activity of GEBx0321, further demonstrating the high compatibility of GEBx0321 with the VLP delivery system.
[0219] Example 10: Optimization of gRNA spacer length
[0220] Spacer length was further optimized to enhance the activity of the GEBx0321-based CRISPR / Cas system.
[0221] In a set of experiments, the HEK293T cells were cultured and transfected following the similar protocol as described in Example 2. Each well received 50 μL of lipoplex containing: GEBx0321 plasmid (harboring GEBx0321 CDS, SEQ ID NO: 28, 400 ng) , gRNA plasmid (harboring 18-25 nt Humanspacer3 spacer, SEQ ID NOs: 141-148, and GEBx0321-PT-V2 sgRNA scaffold, 150 ng) , dsODN (annealed from oligonucleotides SEQ ID NO: 10 and SEQ ID NO: 11, 2.5 pM / well) , LipofectamineTM 3000 (1.5 μL / well) , P3000 (1.5 μL / well) and OptiMemTM to adjust volume. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. Following transfection, subsequent procedures such as DNA extraction, library preparation, amplicon sequencing, and data analysis were performed as described in Example 2.
[0222] Table 15: The nucleotide sequences referred above
[0223] Note: p: phosphorylation modification; *: phosphorothioate (PS) bond; “N” may be any natural or non-natural nucleotide.
[0224] To evaluate the effect of guide RNA spacer length on targeting specificity, we analyzed the number of detected perfect-match and mismatch sites across spacer lengths ranging from 18 to 25nt for the HPA-Humanspacer3 sgRNA. The number of perfect-match and detected off-target (mismatch) sites increased dramatically with longer spacers, peaking at 21–23nt. Spacers shorter than 21nt showed reduced total detected sites overall, while those longer than 23nt exhibited a decline in both on-target and off-target signals. These results indicate that 21-23nt are the optimal spacer lengths for this sgRNA (FIG. 14) .
[0225] To further validate this conclusion, we selected three additional endogenous genomic loci (CD34 / EXM1 / hTTR) for independent verification. In a set of experiments, the HEK293T cells were cultured in DMEM medium supplemented with 10%fetal bovine serum (GibcoTM) . For transfection, cells were seeded in a 96-well plate at 25, 000 cells / well in 100 μL medium 24 hours prior. Transfection was performed using LipofectamineTM 3000 (Invitrogen, Cat. L3000015) according to the manufacturer’s protocol. Each well received 25 μL of lipoplex containing: Cas9 plasmid (harboring GEBx0321 CDS, 150 ng) , gRNA plasmids (encoding sgRNA with different spacer length, Table 16 and GEBx0321-PT-V2 sgRNA scaffold, 75 ng for each plasmid) , LipofectamineTM 3000 (0.6 μL / well) , P3000 (0.6 μL / well) and OptiMemTM to adjust volume. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. DNA extraction amplicon sequencing, and data analysis were performed as described in Example 3.
[0226] Consistent with the results obtained from HPA-Humanspacer3 sgRNA, all three validated endogenous loci exhibited a comparable tendency. At the CD34-sg-4 and EXM1-sg-1 locus, sgRNAs harboring 21nt and 22nt spacer sequences displayed markedly elevated editing activity relative to other spacer lengths. In contrast, the maximal editing activity at the hTTR-sg-1 locus was achieved with a 23nt spacer (FIG. 15) .
[0227] Collectively, the consistent performance across multiple endogenous targets strongly supports that the 21–23 nt spacer length is universally optimal for targeting efficiency in sgRNA design framework.
[0228] Table 16: sgRNA spacer sequences of CD34 / EMX1 / hTTR in this example.
[0229] EXAMPLE 11: GEBx0321-Nickase-mediated in vitro gene editing with dual sgRNAs in mammalian cell lines
[0230] In a set of experiments, the HEK293T cells were cultured transfected following the same protocol as described in Example 3, with the following specific parameters: in DMEM medium supplemented with 10%fetal bovine serum (GibcoTM) . Each well received 25 μL of lipoplex containing: Cas9-nickase plasmid (harboring Cas9-nickase CDS, 150 ng) , gRNA plasmids (encoding sgRNA, 75 ng for each plasmid) . Following transfection, subsequent procedures such as DNA extraction, amplicon sequencing, and data analysis were performed as described in Example 3.
[0231] An in vitro experiment was conducted in HEK293T cells to evaluate the activity of GEBx0321-Nickase with dual guide RNAs. GEBx0321-nickase plasmid harboring GEBx0321-D11A CDS (SEQ ID NO: 191) or GEBx0321-H587A CDS (SEQ ID NO: 193) was co-transfected with one or two gRNA plasmids encoding either sg-1 / 2 sgRNA (SEQ ID NO: 185 / 186) or sg3 / 4 sgRNA (SEQ ID NO: 187 / 188) , including single-sgRNA and paired-sgRNA combinations. Deep sequencing analysis demonstrated that neither GEBx0321-nickase alone with a single sgRNA induced detectable indels. However, when dual sgRNAs were co-delivered, both variants showed measurable editing activity. The GEBx0321-H587A nickase achieved significantly higher indel rates (5.6%and 3.9%) compared to the D11A variant (2.4%and 3.3%) , indicating that the GEBx0321-H857A mutation confers greater editing efficiency under the paired sgRNA setup. (FIG. 16 and FIG. 17) .
[0232] Table 17: Protein, sgRNA, and spacer sequences used in Example 11
[0233] EXAMPLE 12: In vitro gene editing using VLP-delivered GEBx0321-nickase in mammalian cell lines
[0234] The VLP packaging procedure was performed as described in Example 4, except that the gRNA spacers and GEBx0321-nickase were changed.
[0235] For transfection, cells were seeded in a 96-well plate at 20, 000 cells / well in 100 μL medium 24 hours prior. Each well received 10 μL of VLP 50× concentrated stocks. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. DNA extraction, amplicon sequencing, and data analysis were performed as described in Example 3.
[0236] An in vitro experiment was performed in the HEK293T cell line to assess the gene editing activity mediated by GEBx0321-D11A-loaded or GEBx0321-H587A-loaded VLPs. VLPs packaged as described above, carrying GEBx0321-nickase protein and sgRNA including single-sgRNA and paired-sgRNA combinations) , were transfected into the cells. Deep sequencing analysis demonstrated that GEBx0321-nickase still exhibited nickase activity following delivery via VLPs.
[0237] EXAMPLE 13: In vitro gene editing using VLP-delivered GEBx0321-ABE in mammalian cell lines
[0238] Following validation of GEBx0321-nickase activity, the base-editing function of GEBx0321-ABE was assessed using VLP-mediated delivery. GEBx0321-ABE was constructed by fusing ABE8e to the N-terminus of GEBx0321-D11A, with two NLS sequences and a Flag tag incorporated at its N-and C-termini.
[0239] The VLP packaging procedure was performed as described in Example 4, except that the gRNA spacer and GEBx0321-ABE was selected from the sequences in Table 18.
[0240] For transfection, cells were seeded in a 96-well plate at 20, 000 cells / well in 100 μL medium 24 hours prior. Each well received 10 μL of VLP 50× concentrated stocks. Following transfection, cells were maintained at 37℃ with 5%CO2 for 72 hours. DNA extraction, amplicon sequencing, and data analysis were performed as described in Example 3.
[0241] An in vitro experiment was performed in the HEK293T cell line to assess the gene editing activity mediated by GEBx0321-ABE-loaded VLPs at POLQ-NNNNCAAA-sg-1 / sg-2 or CFTR-NNNNCAAA-sg-7 target sites. VLPs packaged as described above, carrying GEBx0321-ABE protein and sgRNA (harboring GEBx0321-PT-V2 sgRNA scaffold, SEQ ID NO: 8 and spacer, SEQ ID NOs: 35, 37-38) , were transfected into the cells. Deep sequencing analysis demonstrated A-to-G base editing efficiencies induced by GEBx0321-ABE at the POLQ-NNNNNCAAA-sg-1 / 2 and CFTR-NNNNCAAA-sg7 target site (FIG. 18) .
[0242] Table 18: Protein, sgRNA and spacer sequences in Example 13
[0243] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1.A virus-like particle comprising:(a) an envelope comprising an envelope glycoprotein;(b) a group-specific antigen (Gag) -polymerase (pol) polyprotein comprising a protease;(c) a fusion protein comprising a Gag polypeptide, an RNA-guided DNA binding agent and a cleavable linker; and(d) a guide RNA (gRNA) capable of binding to a target DNA sequence;wherein an amino acid sequence of the RNA-guided DNA binding agent is selected from the group consisting of: (i) an amino acid sequence of SEQ ID NO: 1; and (ii) an amino acid sequence having at least 90%sequence identity to SEQ ID NO: 1.2.A virus-like particle comprising:(a) an envelope comprising an envelope glycoprotein;(b) a group-specific antigen (Gag) -polymerase (pol) polyprotein comprising a protease;(c) a Gag polypeptide;(d) an RNA-guided DNA binding agent capable of binding to a target DNA sequence; and(e) a guide RNA (gRNA) ;wherein the Gag polypeptide and the RNA-guided DNA binding agent were fused via a cleavable linker located therebetween to form a fusion protein, and the cleavable linker has subsequently been cleaved by the protease of the Gag-pol polyprotein; and wherein an amino acid sequence of the RNA-guided DNA binding agent is selected from the group consisting of: (i) an amino acid sequence of SEQ ID NO: 1; and (ii) an amino acid sequence having at least 90%sequence identity to SEQ ID NO: 1.3.The virus-like particle of claim 1 or 2, wherein the RNA-guided DNA binding agent comprises one or more mutations in an HNH domain and / or a RuvC domain relative to SEQ ID NO: 1, and wherein said one or more mutations result in a loss of DNA cleavage activity in the HNH domain, the RuvC domain, or both.4.The virus-like particle of any one of claims 1-3, wherein the RNA-guided DNA binding agent comprises an amino acid substitution at a position corresponding to residue 11, and / or 587 of SEQ ID NO: 1.5.The virus-like particle of claim 3, wherein said one or more mutations are selected from the group consisting of D11A and H587A, wherein each mutation is at a position corresponding to that of SEQ ID NO: 1.6.The virus-like particle of any one of claims 1-5, wherein the RNA-guided DNA binding agent recognizes a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .7.The virus-like particle of any one of claims 1-6, wherein the fusion protein further comprises one or more nuclear export sequences (NESs) .8.The virus-like particle of claim 7, wherein the fusion protein comprises two NESs, three NESs, four NESs, five NESs, six NESs, seven NESs, eight NESs, nine NESs, or ten NESs; preferably, the fusion protein comprises four NESs.9.The virus-like particle of claim 7 or 8, wherein the cleavable linker is located between the RNA-guided DNA binding agent and the NES (s) .10.The virus-like particle of any one of claims 1-9, wherein the cleavable linker comprises a protease cleavage site.11.The virus-like particle of any one of claims 1-10, wherein the fusion protein further comprises one or more nuclear localization sequences (NLSs) .12.The virus-like particle of claim 11, wherein the fusion protein further comprises two NLSs, three NLSs, four NLSs, or five NLSs; preferably, the fusion protein comprises two NLSs.13.The virus-like particle of any one of claims 1-12, wherein the Gag polypeptide comprises a capsid (CA) polypeptide and / or a matrix (MA) polypeptide.14.The virus-like particle of any one of claims 1-13, wherein the Gag polypeptide is derived from a structural protein of a virus selected from the group consisting of:Moloney murine leukemia virus (MMLV) , Bovine immunodeficiency virus, Simian immunodeficiency virus, Feline immunodeficiency virus, Human immunodeficiency virus (HIV) , Equine infectious anemia virus, Caprine arthritis encephalitis virus, Baboon endogenous virus; or wherein the Gag polypeptide is derived from a human endogenous retrovirus (HERV) .15.The virus-like particle of any one of claims 1-14, wherein the Gag polypeptide is selected from the group consisting of: a Moloney murine leukemia virus (MMLV) -derived Gag polypeptide, and a HIV-1-derived Gag polypeptide.16.The virus-like particle of any one of claims 1-15, wherein the Gag polypeptide is a chimeric Gag.17.The virus-like particle of claim 16, wherein the chimeric Gag comprises: (a) a core-assembly domain selected from the group consisting of: (i) a capsid (CA) domain derived from a structural protein of a first virus, or a functional fragment thereof; and (ii) a capsid (CA) -like domain derived from a first endogenous structural protein, or a functional fragment thereof; and(b) a membrane recruitment domain that is heterologous with the domain of (a) .18.The virus-like particle of claim 17, wherein the first virus is a first Retroviridae virus; optionally, the first Retroviridae virus is selected from the group consisting of Reticuloendotheliosis virus (REV) , Rous sarcoma virus (RSV) , Avian leukosis virus (ALV) , Murine leukemia virus (MLV) , Feline leukemia virus (FeLV) , Bovine leukemia virus (BLV) , Gibbon ape leukemia virus (GaLV) , and Human immunodeficiency virus type 1 (HIV-1) .19.The virus-like particle of claim 17, wherein the first endogenous structural protein is a human endogenous structural protein or animal endogenous structural protein; optionally, the first endogenous structural protein is selected from the group consisting of: ARC, PEG10, PNMA2, HERV-Kcon Gag, Arcl, Asprvl, PNMA1, PNMA3, PNMA4, PNMA5, PNMA6, PNMA7, RTL1, MOAPI, and ZCCHC12.20.The virus-like particle of any one of claims 17-19, wherein the membrane recruitment domain comprises a domain selected from the group consisting of: (a) a matrix (MA) domain derived from a structural protein of a second virus, or a functional fragment thereof; and (b) a matrix (MA) -like domain derived from a second endogenous structural protein, or a functional fragment thereof.21.The virus-like particle of claim 20, wherein the second virus is selected from the group consisting of: Human Immunodeficiency Virus, Human T-lymphotropic virus, Bovine leukemia virus, Murine leukemia virus, Simian immunodeficiency virus, Feline leukemia virus, Avian leukosis virus, Rat leukemia virus, and Moloney Murine Leukemia Virus; preferably, the second virus is Moloney Murine Leukemia Virus.22.The virus-like particle of claim 20, wherein the second endogenous structural protein is selected from the group consisting of: ARC, PEG10, PNMA2, HERV-Kcon Gag, Arcl, Asprvl, PNMA1, PNMA3, PNMA4, PNMA5, PNMA6, PNMA7, RTL1, MOAPI, and ZCCHC12.23.The virus-like particle of any one of claims 1-22, wherein the envelope glycoprotein is selected from the group consisting of: a vesicular stomatitis virus glycoprotein (VSV-G) , a measles virus hemagglutinin (HA) and / or fusion (F) glycoprotein, an influenza virus hemagglutinin (HA) and / or neuraminidase (NA) , a cocal virus glycoprotein, a Moloney murine leukemia virus (MMLV) envelope protein, a baboon endogenous retrovirus (BaEV) envelope protein, an Ebola virus glycoprotein, a Marburg virus glycoprotein, a foamy virus envelope protein, a hepatitis B virus (HBV) glycoprotein, a hepatitis C virus (HCV) glycoprotein, a SARS coronavirus (SARS-CoV) glycoprotein, a respiratory syncytial virus (RSV) glycoprotein, a human parainfluenza virus glycoprotein, a human T-cell lymphotropic virus type 1 (HTLV-1) glycoprotein, a Ross River virus glycoprotein, a rabies virus glycoprotein, a Mokola virus glycoprotein, a Semliki Forest virus glycoprotein, a Sindbis virus glycoprotein, a Venezuelan equine encephalitis virus glycoprotein, a Sendai virus glycoprotein, a baculovirus envelope glycoprotein (e.g., GP64) , an Eastern equine encephalitis virus (EEEV) glycoprotein, a Lymphocytic choriomeningitis virus (LCMV) glycoprotein, a Chandipura virus (CHPV) glycoprotein, a Zika virus envelope protein, and variants thereof retaining membrane fusion properties.24.The virus-like particle of any one of claims 1-23, wherein the envelope glycoprotein is a variant viral envelope protein that comprises one or more amino acid modifications selected from the group consisting of substitutions, deletions, insertions, and truncations, which reduce binding of the viral envelope protein to its receptor.25.The virus-like particle of any one of claims 1-24, wherein the virus-like particle further comprises a targeting polypeptide.26.The virus-like particle of claim 25, wherein the targeting polypeptide is selected from the group consisting of: single chain variable fragment (scFv) , nanobody, and multidomain fusion protein (MDF) .27.The virus-like particle of any one of claims 1-26, wherein the gRNA is a single guide RNA (sgRNA) , comprising:(a) a scaffold sequence of any one of SEQ ID NOs: 7-8; or(b) a scaffold sequence having at least 90%identity to any one of SEQ ID NOs: 7-8.28.The virus-like particle of any one of claims 1-27, wherein the gRNA comprises a spacer sequence, and the spacer sequence (a) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (b) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (c) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148.29.A virus-like particle comprising on a surface of the particle:(a) an envelope glycoprotein derived from BaEV; and(b) a CD58 extracellular domain sequence, a CD80 or CD86 extracellular domain sequence, an anti-CD3 antibody or antigen-binding fragment, or a combination thereof.30.A plurality of polynucleotides comprising:(i) a first polynucleotide comprising a nucleic acid sequence encoding an envelope glycoprotein as defined in any one of claims 1-28;(ii) a second polynucleotide comprising a nucleic acid sequence encoding a fusion protein as defined in any one of claims 1-28;(iii) a third polynucleotide comprising a nucleic acid sequence encoding a Gag-pol polyprotein as defined in any one of claims 1-28; and(iv) a fourth polynucleotide comprising a nucleic acid sequence encoding a gRNA as defined in any one of claims 1-28.31.An RNA-guided DNA binding agent, comprising an amino acid sequence having at least 90%sequence identity to SEQ ID NO: 1, wherein said amino acid sequence comprises one or more mutations in an HNH domain and / or a RuvC domain relative to SEQ ID NO: 1, and wherein said one or more mutations result in a loss of DNA cleavage activity in the HNH domain, the RuvC domain, or both.32.The RNA-guided DNA binding agent of claim 31, wherein said one or more mutations comprise an amino acid substitution at a position corresponding to residue 11, and / or 587 of SEQ ID NO: 1.33.The RNA-guided DNA binding agent of claim 31 or 32, wherein said one or more mutations are selected from the group consisting of D11A and H587A, wherein each mutation is at a position corresponding to that of SEQ ID NO: 1.34.The RNA-guided DNA binding agent of any one of claims 31-33, wherein the RNA-guided DNA binding agent recognizes a protospacer adjacent motif (PAM) having a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .35.A chimeric polypeptide comprising (i) the RNA-guided DNA binding agent of any one of claims 31-34; and (ii) an effector domain.36.The chimeric polypeptide of claim 35, wherein the effector domain is selected from the group consisting of: a nuclear localization signal sequence, a nuclear export signal sequence, a cell-penetrating peptide sequence, an affinity tag sequence, a deaminase sequence, a reverse transcriptase sequence, a recombinase sequence, a methyltransferase sequence, a methylase sequence, an acetylase sequence, an acetyltransferase sequence, a transcriptional activator sequence, a transcriptional repressor domain sequence, a cryptochrome sequence, a light inducible / controllable domain sequence, a chemically inducible / controllable domain sequence, and a replication initiation protein sequence.37.An engineered, non-naturally occurring CRISPR / Cas system comprising:(a) an RNA-guided DNA binding agent of any one of claims 31-34 or a polynucleotide encoding such RNA-guided DNA binding agent; and(b) at least one engineered guide RNA (gRNA) or at least one engineered polynucleotide encoding the engineered gRNA, wherein said engineered gRNA comprises a spacer sequence that is complementary to a target nucleic acid.38.The CRISPR / Cas system of claim 37, wherein the gRNA is a single guide RNA (sgRNA) , comprising: (a) a scaffold sequence of any one of SEQ ID NOs: 7-8; or (b) a scaffold sequence having at least 90%identity to any one of SEQ ID NOs: 7-8.39.The CRISPR / Cas system of claim 37 or 38, wherein the spacer sequence (a) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (b) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (c) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148.40.The CRISPR / Cas system of any one of claims 38-39, wherein the sgRNA comprises:(a) a scaffold sequence of any one of SEQ ID NOs: 7-8; or (b) a scaffold sequence having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, or at least 90%identity to any one of SEQ ID NOs: 7-8.41.The CRISPR / Cas system of claim 37-40, wherein the spacer sequence (a) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (b) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (c) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148.42.The CRISPR / Cas system of any one of claims 37-41, wherein the CRISPR / Cas system further comprises a donor template nucleic acid.43.A guide RNA (gRNA) comprising(a) a spacer sequence, wherein the spacer sequence: (i) comprises a sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; (ii) has at least 15 contiguous nucleotides of the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; or (iii) has at least 70%sequence identity to the sequence of any one of SEQ ID NOs: 29-52, 53-59, 91-104, 111-114, and 141-148; and(b) a binding segment capable of binding to RNA-guided DNA binding agent of any one of claims 31-34; wherein the binding segment comprises a tracrRNA sequence and a direct repeat (DR) sequence that hybridizes to form a double-stranded RNA (dsRNA) duplex.44.The gRNA of claim 43, wherein the gRNA is a dual guide RNA or a single guide RNA (sgRNA) .45.The gRNA of claim 44, wherein the sgRNA comprises: (a) a scaffold sequence of any one of SEQ ID NOs: 7-8; or(b) a scaffold sequence having at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, or at least 90%identity to any one of SEQ ID NOs: 7-8.46.A method of making a virus-like particle, comprising transfecting the plurality of polynucleotides of claim 30, into a cell and expressing components of the virus-like particle from the plurality of polynucleotides in the cell, thereby allowing the virus-like particle to spontaneously assemble in the cell.47.A method of editing a nucleic acid molecule in a target cell, comprising contacting the target cell with the virus-like particle of any one of claims 1-29, the RNA-guided DNA binding agent of any one of claim 31-34, the chimeric polypeptide of any one of claims 35-36, the CRISPR / Cas system of any one of claims 37-42, or the guide RNA of any one of claims 43-45, thereby installing one or more modifications to the nucleic acid molecule at a target site.48.Use of the virus-like particle of any one of claims 1-29, the RNA-guided DNA binding agent of any one of claim 31-34, the chimeric polypeptide of any one of claims 35-36, the CRISPR / Cas system of any one of claims 37-42, or the guide RNA of any one of claims 43-45, in treating a disorder, comprising editing a target gene, wherein the target gene comprises a protospacer adjacent motif (PAM) comprising a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .49.A method for treating a disorder in a subject, comprising: administering to the subject the virus-like particle of any one of claims 1-29, the RNA-guided DNA binding agent of any one of claim 31-34, the chimeric polypeptide of any one of claims 35-36, the CRISPR / Cas system of any one of claims 37-42, or the guide RNA of any one of claims 43-45;wherein the virus-like particle, the RNA-guided DNA binding agent, the chimeric polypeptide, the CRISPR / Cas system, or the guide RNA is capable of editing a target gene in the subject, or participating in the editing thereof, andwherein the target gene comprises a protospacer adjacent motif (PAM) comprising a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .50.Use of the RNA-guided DNA binding agent of any one of claim 31-34 or the CRISPR / Cas system of any one of claims 37-42 in recognizing a protospacer adjacent motif (PAM) comprising a sequence of NNNNCAAA, NNNCAAA, NNCAAA, NCAAA, or CAAA; wherein each “N” represents any nucleotide selected from the group consisting of adenine (A) , thymine (T) , cytosine (C) , and guanine (G) .51.Use of the virus-like particle of any one of claims 1-29, the RNA-guided DNA binding agent of any one of claim 31-34, the chimeric polypeptide of any one of claims 35-36, the CRISPR / Cas system of any one of claims 37-42, or the guide RNA of any one of claims 43-45, in the manufacture of a medicament for treating a genetic disorder.
